<?xml version="1.0" encoding="UTF-8" standalone="no"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD Journal Publishing DTD v2.3 20070202//EN" "journalpublishing.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" article-type="review-article" dtd-version="2.3" xml:lang="EN">
<front>
<journal-meta>
<journal-id journal-id-type="publisher-id">Front. Endocrinol.</journal-id>
<journal-title>Frontiers in Endocrinology</journal-title>
<abbrev-journal-title abbrev-type="pubmed">Front. Endocrinol.</abbrev-journal-title>
<issn pub-type="epub">1664-2392</issn>
<publisher>
<publisher-name>Frontiers Media S.A.</publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="doi">10.3389/fendo.2024.1377918</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Endocrinology</subject>
<subj-group>
<subject>Review</subject>
</subj-group>
</subj-group>
</article-categories>
<title-group>
<article-title>Reassessing type 2 diabetes in adolescents and its management strategies based on insulin resistance</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author" equal-contrib="yes">
<name>
<surname>Jia</surname>
<given-names>QianYou</given-names>
</name>
<xref ref-type="aff" rid="aff1">
<sup>1</sup>
</xref>
<xref ref-type="author-notes" rid="fn003">
<sup>&#x2020;</sup>
</xref>
<uri xlink:href="https://loop.frontiersin.org/people/2576198"/>
<role content-type="https://credit.niso.org/contributor-roles/writing-original-draft/"/>
<role content-type="https://credit.niso.org/contributor-roles/writing-review-editing/"/>
</contrib>
<contrib contrib-type="author" equal-contrib="yes">
<name>
<surname>Zhang</surname>
<given-names>YanMin</given-names>
</name>
<xref ref-type="aff" rid="aff1">
<sup>1</sup>
</xref>
<xref ref-type="author-notes" rid="fn003">
<sup>&#x2020;</sup>
</xref>
<role content-type="https://credit.niso.org/contributor-roles/writing-original-draft/"/>
</contrib>
<contrib contrib-type="author" corresp="yes">
<name>
<surname>Zhang</surname>
<given-names>BaoFeng</given-names>
</name>
<xref ref-type="aff" rid="aff1">
<sup>1</sup>
</xref>
<xref ref-type="author-notes" rid="fn001">
<sup>*</sup>
</xref>
<role content-type="https://credit.niso.org/contributor-roles/conceptualization/"/>
<role content-type="https://credit.niso.org/contributor-roles/writing-review-editing/"/>
</contrib>
<contrib contrib-type="author" corresp="yes">
<name>
<surname>An</surname>
<given-names>XueDong</given-names>
</name>
<xref ref-type="aff" rid="aff2">
<sup>2</sup>
</xref>
<xref ref-type="author-notes" rid="fn001">
<sup>*</sup>
</xref>
<uri xlink:href="https://loop.frontiersin.org/people/805231"/>
<role content-type="https://credit.niso.org/contributor-roles/conceptualization/"/>
<role content-type="https://credit.niso.org/contributor-roles/writing-original-draft/"/>
<role content-type="https://credit.niso.org/contributor-roles/writing-review-editing/"/>
</contrib>
</contrib-group>
<aff id="aff1">
<sup>1</sup>
<institution>Department of Pediatrics, Rizhao Hospital of Traditional Chinese Medicine</institution>, <addr-line>Rizhao</addr-line>, <country>China</country>
</aff>
<aff id="aff2">
<sup>2</sup>
<institution>Department of Endocrinology &amp; Diabetes Vascular Function Laboratory, Guang&#x2019;anmen Hospital of China Academy of Chinese Medical Sciences</institution>, <addr-line>Beijing</addr-line>, <country>China</country>
</aff>
<author-notes>
<fn fn-type="edited-by">
<p>Edited by: Brenda Kohn, New York University, United States</p>
</fn>
<fn fn-type="edited-by">
<p>Reviewed by: Ershun Liang, Qilu Hospital of Shandong University, China</p>
<p>Meera Ladwa, Barts Health NHS Trust, United Kingdom</p>
</fn>
<fn fn-type="corresp" id="fn001">
<p>*Correspondence: XueDong An, <email xlink:href="mailto:Doctor_anxd@163.com">Doctor_anxd@163.com</email>; BaoFeng Zhang, <email xlink:href="mailto:29829397@qq.com">29829397@qq.com</email>
</p>
</fn>
<fn fn-type="equal" id="fn003">
<p>&#x2020;These authors have contributed equally to this work and share first authorship</p>
</fn>
</author-notes>
<pub-date pub-type="epub">
<day>19</day>
<month>06</month>
<year>2024</year>
</pub-date>
<pub-date pub-type="collection">
<year>2024</year>
</pub-date>
<volume>15</volume>
<elocation-id>1377918</elocation-id>
<history>
<date date-type="received">
<day>28</day>
<month>01</month>
<year>2024</year>
</date>
<date date-type="accepted">
<day>05</day>
<month>06</month>
<year>2024</year>
</date>
</history>
<permissions>
<copyright-statement>Copyright &#xa9; 2024 Jia, Zhang, Zhang and An</copyright-statement>
<copyright-year>2024</copyright-year>
<copyright-holder>Jia, Zhang, Zhang and An</copyright-holder>
<license xlink:href="http://creativecommons.org/licenses/by/4.0/">
<p>This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.</p>
</license>
</permissions>
<abstract>
<p>With changes in lifestyle behaviors, including dietary structure and habits, the prevalence of Youth-onset Type 2 Diabetes Mellitus (YODM) has increased 2 to 3 times compared to 30 years ago. YODM patients experience complications earlier, progress faster, and exhibit more severe symptoms. However, limited and inconclusive direct evidence, coupled with poor patient compliance, poses challenges in the clinical management of YODM. Apart from the continuous decline in pancreatic &#x3b2;-cell function and quantity, tissue-specific insulin resistance (IR) is also a typical characteristic of YODM. The main mechanisms of IR in YODM involve different aspects such as obesity, dietary imbalance, abnormal substance metabolism, chronic inflammation, oxidative stress, and hormonal fluctuations during adolescence. For the comprehensive management of YODM, besides achieving good control of blood glucose levels, it may be necessary to apply the most appropriate methods considering the uniqueness of the patient population and the specifics of the disease. Early identification and detection of the disease are crucial. Precise screening of patients with well-functioning pancreatic insulin &#x3b2;-cells, primarily characterized by IR and obesity, represents the population most likely to achieve diabetes remission or reversal through lifestyle modifications, medications, or even surgical interventions. Additionally, considering potential emotional disorders or the impact of adolescent hormones in these patients, health education for patients and caregivers is essential to make them aware of the long-term benefits of well-controlled blood glucose. In conclusion, adopting comprehensive management measures to achieve diabetes remission or reversal is the ideal goal. Controlling high blood glucose, obesity, and other risk factors related to diabetes complications is the next priority to delay the occurrence and progression of complications. A comprehensive perspective on IR provides insights and references for identifying YODM and its management strategies.</p>
</abstract>
<kwd-group>
<kwd>youth-onset diabetes mellitus</kwd>
<kwd>insulin resistance</kwd>
<kwd>obesity</kwd>
<kwd>mechanisms</kwd>
<kwd>management strategies</kwd>
<kwd>diabetes remission</kwd>
</kwd-group>
<counts>
<fig-count count="2"/>
<table-count count="1"/>
<equation-count count="0"/>
<ref-count count="158"/>
<page-count count="14"/>
<word-count count="7297"/>
</counts>
<custom-meta-wrap>
<custom-meta>
<meta-name>section-in-acceptance</meta-name>
<meta-value>Pediatric Endocrinology</meta-value>
</custom-meta>
</custom-meta-wrap>
</article-meta>
</front>
<body>
<sec id="s1" sec-type="intro">
<label>1</label>
<title>Introduction</title>
<p>The International Diabetes Federation pointed out in its 2021 conference that globally, 537 million adults (20&#x2013;79 years old) are affected by Diabetes Mellitus (DM), and it is projected to rise to 784 million by the year 2045. Changes in dietary structure (consumption of high-calorie foods) and lifestyle habits (such as staying up late and insufficient physical activity) contribute to a trend of younger onset Type 2 Diabetes Mellitus (T2DM). Research indicates that the prevalence of Youth-onset Type 2 Diabetes Mellitus (YODM), that occurs during adolescence (typically between the ages of 10 and 18), has increased 2 to 3 times compared to 30 years ago, with an estimated 41,600 new cases worldwide in 2021, particularly higher rates reported in China, India, and the United States (<xref ref-type="bibr" rid="B1">1</xref>&#x2013;<xref ref-type="bibr" rid="B3">3</xref>).</p>
<p>While comprehensive management for adult DM patients is becoming increasingly standardized across various aspects such as diagnosis, monitoring, prevention, and treatment, the same cannot be said for YODM. This is primarily due to its unique characteristics, including the need for improved systemic management measures, rapid disease progression, poor compliance, and prominent psychological and emotional challenges. Data from &#x201c;Healthy People 2020&#x201d; reveals that only 27.1% of adolescents meet the recommended levels of physical activity, and just 31.7% get adequate sleep (<xref ref-type="bibr" rid="B4">4</xref>). Dietary imbalances are common among YODM, impacting obesity and psychosocial functionality. The Treatment Options for Type 2 Diabetes in Adolescents and Youth Study (TODAY) indicates that 20% and 6% of young individuals exhibit subclinical or clinical binge-eating behavior (<xref ref-type="bibr" rid="B5">5</xref>). These unfavorable lifestyle habits contribute to the rising incidence of YODM, and information about its pathophysiology is mostly derived from adult studies (<xref ref-type="bibr" rid="B6">6</xref>). Considering the unique nature of the affected population, YODM patients face a higher risk of depression and other mental health disorders, with an estimated depression prevalence exceeding 20% (<xref ref-type="bibr" rid="B7">7</xref>, <xref ref-type="bibr" rid="B8">8</xref>). This not only affects blood glucose control but also directly contributes to lower patient compliance (<xref ref-type="bibr" rid="B9">9</xref>). In comparison to adult T2DM, YODM has an earlier onset, a faster decline in pancreatic &#x3b2;-cell function, and a higher likelihood of complications if not controlled promptly (<xref ref-type="bibr" rid="B10">10</xref>). Approximately 8 years after YODM diagnosis, 72% of T2DM patients experience at least one complication (<xref ref-type="bibr" rid="B11">11</xref>). As a result, YODM has become an increasingly serious global health issue for adolescents and young people, demanding more attention (<xref ref-type="bibr" rid="B12">12</xref>&#x2013;<xref ref-type="bibr" rid="B14">14</xref>).</p>
<p>In addition to the continuous decline in pancreatic &#x3b2;-cell function and quantity, tissue-specific insulin resistance (IR) is also a typical characteristic of T2DM, including YODM, holding a significant position in its occurrence and development (<xref ref-type="bibr" rid="B15">15</xref>&#x2013;<xref ref-type="bibr" rid="B17">17</xref>). Therefore, focusing on IR allows for the transfer of some T2DM management strategies to YODM. Simultaneously, expectations for the treatment goals of some YODM patients should be elevated, including diabetes remission, defined as having an HbA1c below 6.5% for at least one year without the use of glucose-lowering medications according to the standards recommended by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). And the most ideal state, crucial for long-term improvements in quality of life and survival (<xref ref-type="bibr" rid="B18">18</xref>). This is followed by controlling risk factors to delay the occurrence and progression of complications. However, the immediate priority lies in the early identification of adolescent IR or even YODM, enabling the prompt alteration of metabolic abnormalities. Thus, early detection and intensive management of YODM are paramount (<xref ref-type="bibr" rid="B19">19</xref>). We first summarize the clinical characteristics (specificities, risk factors) of YODM, focusing on IR, and then explores management strategies for YODM, aiming to provide reference points for the clinical understanding and management of YODM.</p>
</sec>
<sec id="s2">
<label>2</label>
<title>Comprehensive and accurate understanding of YODM is key to developing more effective comprehensive management strategies</title>
<sec id="s2_1">
<label>2.1</label>
<title>More specific characteristics of YODM compared to adult T2DM</title>
<p>Both adult T2DM and YODM share common risk factors, pathological changes, and clinical manifestations as they both belong to the diabetes category. Common risk factors include obesity, family history, shared pathological changes such as reduced insulin sensitivity and insufficient insulin secretion, and common clinical manifestations like polydipsia, polyuria, increased appetite, and fatigue (<xref ref-type="bibr" rid="B20">20</xref>). However, due to the younger age of the YODM patient population, they exhibit unique clinical features, making management more challenging, disease progression faster, and the condition more severe (<xref ref-type="bibr" rid="B21">21</xref>).</p>
<sec id="s2_1_1">
<label>2.1.1</label>
<title>Earlier onset of complications, faster disease progression, and more severe symptoms in YODM patients</title>
<p>Long-term follow-up reports from the TODAY study (average diabetes duration of 13.3 &#xb1; 1.8 years) show that YODM patients have higher rates of diabetic nephropathy (54.8%), neuropathy (32.4%), and retinopathy (13.7%) (<xref ref-type="bibr" rid="B22">22</xref>). The SEARCH study also indicates that compared to Type 1 Diabetes Mellitus (T1DM) patients, YODM patients have higher occurrence rates of diabetic nephropathy (19.9% vs. 5.8%), retinopathy (9.1% vs. 5.6%), and peripheral neuropathy (17.7% vs. 8.5%) (<xref ref-type="bibr" rid="B11">11</xref>). Although diabetic ketoacidosis is not a common initial presentation in YODM, its frequency can be as high as 3% to 11%, with high blood glucose and hyperosmolarity states being rare (<xref ref-type="bibr" rid="B23">23</xref>, <xref ref-type="bibr" rid="B24">24</xref>).</p>
</sec>
<sec id="s2_1_2">
<label>2.1.2</label>
<title>Limited and challenging clinical management due to insufficient evidence and poor compliance in YODM patients</title>
<p>There are relatively few interventional clinical studies focused on YODM, with major studies including the TODAY study and SEARCH study. Ethical considerations, along with the transitional phases YODM patients undergo in physiological, psychological, and social aspects, make it challenging to conduct diagnostic and interventional clinical studies due to the significant emotional disturbances exhibited by patients. Despite partial references to the pathophysiology evidence from adult diabetes studies (<xref ref-type="bibr" rid="B6">6</xref>), the scarcity of such studies poses limitations. A study in Korea assessing the prevalence and characteristics of YODM using the National Health Insurance Service (NHIS) database highlighted non-adherence to treatment and low compliance as major obstacles in managing YODM patients (<xref ref-type="bibr" rid="B19">19</xref>). Adolescents (10 to 20 years old) are more likely to display medical non-adherence, and data indicates that the younger the age, the lower the blood glucose control rate in T2DM patients (<xref ref-type="bibr" rid="B25">25</xref>&#x2013;<xref ref-type="bibr" rid="B27">27</xref>). YODM patients relying solely on lifestyle modifications and metformin for blood glucose control exhibit a high rate of poor blood glucose control, reaching 51.7% (<xref ref-type="bibr" rid="B28">28</xref>). Therefore, effective strategies and interventions are needed to manage YODM and reduce the risks of microvascular and macrovascular complications, addressing compliance issues more effectively than seen in adult patients.</p>
</sec>
</sec>
<sec id="s2_2">
<label>2.2</label>
<title>Risk factors for the occurrence and development of YODM</title>
<p>Critical driving factors for the prevalence of YODM include both genetic factors inherited from parents and acquired risk factors related to oneself, such as obesity, unhealthy lifestyle habits, and psychological factors.</p>
<sec id="s2_2_1">
<label>2.2.1</label>
<title>Genetic factors inherited from parents</title>
<p>For the majority of YODM cases (92%), genetic factors should be considered, particularly for patients with atypical presentations and/or a positive family history (<xref ref-type="bibr" rid="B23">23</xref>, <xref ref-type="bibr" rid="B29">29</xref>). If one parent has T2DM, the estimated lifelong risk for their child developing T2DM is 40%, and if both parents have T2DM, the risk increases to as much as 70% (<xref ref-type="bibr" rid="B30">30</xref>, <xref ref-type="bibr" rid="B31">31</xref>). Research also suggests that whether maternal diabetes is diagnosed during pregnancy or post-pregnancy, it is associated with poor blood glucose control and reduced glomerular filtration rate in YODM patients (<xref ref-type="bibr" rid="B32">32</xref>). Interestingly, a study in Denmark involving 2,448,753 individuals found that offspring of mothers with gestational hypertension (HR=1.37) or preeclampsia (HR=1.62) have a higher risk of developing T2DM (<xref ref-type="bibr" rid="B33">33</xref>), possibly due to intrauterine growth restriction caused by imbalanced nutrient intake leading to fetal adipose tissue and pancreatic &#x3b2;-cell dysfunction (<xref ref-type="bibr" rid="B34">34</xref>). The Progress in Genetic studies of youth-onset diabetes (ProDiGY) consortium conducted a genome-wide association study on YODM, identifying seven crucial loci in the genome, including rs7903146 in TCF7L2, rs72982988 near MC4R, rs200893788 in CDC123, rs2237892 in KCNQ1, rs937589119 in IGF2BP2, rs113748381 in SLC16A11, and rs2604566 in CPEB2, which may play a significant role in early detection of YODM in the future (<xref ref-type="bibr" rid="B35">35</xref>).</p>
</sec>
<sec id="s2_2_2">
<label>2.2.2</label>
<title>Acquired risk factors</title>
<p>The most crucial acquired risk factor for the development of YODM is obesity, primarily attributed to unhealthy dietary or exercise habits (<xref ref-type="bibr" rid="B36">36</xref>, <xref ref-type="bibr" rid="B37">37</xref>). In recent years, with the widespread adoption of fast food culture and the increased consumption of ultra-processed foods, the proportion of adolescents consuming high-sugar and high-fat foods has significantly risen. Research indicates that high-sugar diets can lead to insulin resistance and fatty liver, thereby increasing the risk of DM (<xref ref-type="bibr" rid="B38">38</xref>). Moreover, high-fat diets not only cause weight gain but also affect insulin secretion and function (<xref ref-type="bibr" rid="B39">39</xref>). For instance, a study involving American adolescents found that those who consumed sugar-sweetened beverages daily had a significantly higher risk of obesity and T2DM compared to their peers who did not consume such beverages (<xref ref-type="bibr" rid="B40">40</xref>). Similarly, diets high in saturated and trans fats are associated with decreased insulin sensitivity and poor glycemic control (<xref ref-type="bibr" rid="B41">41</xref>). A prospective cohort study of adolescents also pointed out that a high-energy fast food diet is significantly associated with elevated fasting blood glucose levels and the occurrence of prediabetic symptoms (<xref ref-type="bibr" rid="B42">42</xref>).</p>
<p>Over the past few decades, the number of obese adolescents has been steadily increasing in many countries (<xref ref-type="bibr" rid="B43">43</xref>). Estimates for childhood obesity from 2017 to March 2020 show prevalence rates of 20.7% for children aged 6 to 11 and 22.2% for children aged 12 to 19 (<xref ref-type="bibr" rid="B44">44</xref>). As a major risk factor for the development of T2DM, the rise in body mass index (BMI) in adolescents is associated with an increased risk of being diagnosed with T2DM at a young age (<xref ref-type="bibr" rid="B45">45</xref>). Meta-analysis results for 228,184 participants show that the prevalence of T2DM in obese individuals is 1.3%, which is 13 times higher than in normal-weight individuals, and the prevalence of prediabetes is three times higher in obese individuals compared to normal individuals (<xref ref-type="bibr" rid="B46">46</xref>). Furthermore, a multicenter cross-sectional study on 2,448 adolescents with T2DM showed prevalence rates of 10.4% for overweight and 79.4% for obesity (<xref ref-type="bibr" rid="B47">47</xref>). Adolescents are in a transitional phase during puberty, making many patients simultaneously experience emotional disturbances. Current research indicates that emotional disorders can lead to the onset of diabetes and exacerbate its severity. The estimated prevalence of depression in T2DM patients is 25%, and it is associated with poorer blood glucose control in these patients (<xref ref-type="bibr" rid="B9">9</xref>, <xref ref-type="bibr" rid="B48">48</xref>). An analysis of data from the Taiwan National Health Insurance Research Database from 2001 to 2010 found that, compared to reactive depression patients responsive to antidepressants, patients with treatment-resistant depression were more likely to be diagnosed with T2DM in later life (HR 1.51) (<xref ref-type="bibr" rid="B49">49</xref>). Additionally, obesity, IR, and hypoglycemic abnormalities may result in relatively poor cognitive function in adolescents with both T2DM and obesity (<xref ref-type="bibr" rid="B50">50</xref>).</p>
</sec>
</sec>
</sec>
<sec id="s3">
<label>3</label>
<title>IR affects the occurrence and development of YODM</title>
<sec id="s3_1">
<label>3.1</label>
<title>IR</title>
<p>In addition to the continuous decline in function and quantity of pancreatic &#x3b2;-cells, tissue-specific IR is also a typical characteristic of T2DM. When the main target tissues of insulin, such as muscles, fat, and the liver, fail to respond appropriately to insulin, insulin sensitivity decreases continuously, making glucose less likely to be cleared from the bloodstream. Tissues begin to exhibit IR, leading to increased insulin production by the pancreas or presenting as hyperinsulinemia (<xref ref-type="bibr" rid="B51">51</xref>). Research has confirmed that IR plays a crucial role in the occurrence and development of various metabolic disorders, including non-alcoholic fatty liver disease (NAFLD), metabolic syndrome, obesity, hypertension, and cardiovascular diseases (<xref ref-type="bibr" rid="B52">52</xref>, <xref ref-type="bibr" rid="B53">53</xref>). Chronic hyperinsulinemia resulting from IR can also lead to a reduction in pancreatic &#x3b2;-cell mass (<xref ref-type="bibr" rid="B54">54</xref>).</p>
<p>Currently, the primary mechanisms of IR involve abnormalities in substance metabolism, chronic inflammation, oxidative stress, among other aspects (<xref ref-type="bibr" rid="B55">55</xref>). Firstly, excessive energy intake promotes an increase in free fatty acids (FFA) and lipid deposition, leading to IR (<xref ref-type="bibr" rid="B56">56</xref>). AMP-activated protein kinase (AMPK), as an AMP-dependent protein kinase, is a key molecule in regulating biological energy metabolism. Studies have shown that activated AMPK can enhance insulin sensitivity and promote glucose uptake (<xref ref-type="bibr" rid="B57">57</xref>). Protein tyrosine phosphatase 1B (PTP1B), a widely expressed prototype non-receptor tyrosine phosphatase, is a critical negative regulator in insulin signal transduction. Overexpression in adipose tissue can lead to dephosphorylation of insulin receptors and inhibit insulin signal transduction (<xref ref-type="bibr" rid="B58">58</xref>). GLUT4 is an insulin-dependent transmembrane carrier protein that facilitates the translocation of glucose on the cell membrane. IR leads to reduced glucose uptake and is associated with impaired GLUT4 translocation (<xref ref-type="bibr" rid="B59">59</xref>).</p>
<p>Certainly, there is ample evidence indicating that chronic inflammation is pervasive throughout the course of DM, and it also influences IR (<xref ref-type="bibr" rid="B60">60</xref>). Macrophages can be classified into two different subtypes based on their activation status: M1 polarization, which promotes inflammation and is associated with reduced insulin sensitivity (<xref ref-type="bibr" rid="B61">61</xref>), and M2 polarization, which inhibits inflammation and is associated with enhanced insulin sensitivity (<xref ref-type="bibr" rid="B62">62</xref>). Activation of the NF-&#x3ba;B and JNK pathways due to pro-inflammatory status increases the secretion of various inflammatory mediators, including tumor necrosis factor-alpha (TNF-&#x3b1;), interleukin-1 beta (IL-1&#x3b2;), and interleukin-6 (IL-6), leading to the promotion of IR (<xref ref-type="bibr" rid="B63">63</xref>&#x2013;<xref ref-type="bibr" rid="B65">65</xref>). Oxidative stress and inflammation often coexist and mutually influence each other in the host. Reactive oxygen species can stimulate the production of inflammatory factors, and, in turn, cellular inflammatory factors can promote the generation of oxygen free radicals (<xref ref-type="bibr" rid="B66">66</xref>). Oxidative stress reduces the translocation of IRS-1, decreases protein kinase B (PKB) phosphorylation, and lowers GLUT-4 expression (<xref ref-type="bibr" rid="B67">67</xref>, <xref ref-type="bibr" rid="B68">68</xref>).</p>
</sec>
<sec id="s3_2">
<label>3.2</label>
<title>Key role of IR in the occurrence and development of YODM</title>
<p>Existing clinical studies confirm that both insulin sensitivity and insulin secretion are impaired in YODM patients (<xref ref-type="bibr" rid="B69">69</xref>). Genetic-related &#x3b2;-cell dysfunction has been found in East Asian adolescents, and it is significantly associated with the development of T2DM even with mild decreases in insulin sensitivity (<xref ref-type="bibr" rid="B70">70</xref>). In contrast, IR is prevalent in the Indian population and may manifest as early as in neonates (<xref ref-type="bibr" rid="B71">71</xref>). The Restoring Insulin Secretion (RISE) study indicates that compared to adults with T2DM, YODM exhibits more severe IR, higher insulin secretion demand, and lower insulin clearance rates (<xref ref-type="bibr" rid="B15">15</xref>). A comparative study of YODM diagnosed within 1.5 years, matched with non-T2DM individuals in terms of BMI, showed a 75% decrease in the first-phase and a 55% decrease in the second-phase insulin secretion in YODM, accompanied by severe peripheral and hepatic IR (<xref ref-type="bibr" rid="B69">69</xref>). This may be attributed to hormonal changes affecting insulin sensitivity during puberty, and the more severe obesity issues in adolescent patients also affect peripheral tissue insulin sensitivity (<xref ref-type="bibr" rid="B72">72</xref>). IR may prompt &#x3b2;-cells to secrete more insulin, leading to earlier &#x3b2;-cell failure. Dysfunction, rather than death, is a common &#x3b2;-cell defect in T2D (<xref ref-type="bibr" rid="B73">73</xref>). Therefore, focusing on IR in the early stages of YODM and conducting intervention studies may improve &#x3b2;-cell function to some extent. A cross-sectional study, including 79 adolescents aged 10 to 18, assessed body composition indicators: body mass index (BMI), body fat percentage, waist circumference, and subcutaneous fat. IR was diagnosed in 29.1% of patients, and these body composition indicators were all correlated with IR (<xref ref-type="bibr" rid="B74">74</xref>) (<xref ref-type="fig" rid="f1">
<bold>Figure&#xa0;1</bold>
</xref>).</p>
<fig id="f1" position="float">
<label>Figure&#xa0;1</label>
<caption>
<p>Key role of IR in the occurrence and development of YODM.</p>
</caption>
<graphic mimetype="image" mime-subtype="tiff" xlink:href="fendo-15-1377918-g001.tif"/>
</fig>
<p>Considering the causes of obesity-induced DM, IR plays a crucial role (<xref ref-type="bibr" rid="B75">75</xref>, <xref ref-type="bibr" rid="B76">76</xref>). A study conducted in Japan using intravenous glucose tolerance testing revealed IR in both obese non-diabetic adolescents and YODM individuals (<xref ref-type="bibr" rid="B77">77</xref>). Additionally, one of the major complications of obesity is IR, leading to disturbances in carbohydrate metabolism. Compared to normal-weight children, overweight and obese children have a higher incidence of IR (<xref ref-type="bibr" rid="B78">78</xref>). In the early stages of the disease, pancreatic &#x3b2;-cells can compensate for IR by increasing insulin secretion in the pathogenesis of glucose intolerance. Compensatory hyperinsulinemia induces increased appetite and weight gain. With the decline in pancreatic &#x3b2;-cell function and inadequate insulin secretion, the transition from IR to impaired glucose tolerance and then to T2DM occurs (<xref ref-type="bibr" rid="B79">79</xref>). Androutsos and colleagues applied principal component analysis to a health growth study cohort of over 2000 Greek children aged 9&#x2013;13. They observed a positive correlation between a combination of high screen time, short sleep duration, and high sugary beverage consumption with HOMA-IR, while a combination of high to moderate-intensity physical activity and frequent eating showed a negative correlation with HOMA-IR (<xref ref-type="bibr" rid="B80">80</xref>). Dietary imbalance is prevalent in YODM and affects obesity and psychosocial function.</p>
<p>In the TODAY study, 20% and 6% of young people exhibited subclinical and clinical binge eating (<xref ref-type="bibr" rid="B5">5</xref>). In the SEARCH study, 50.3% of youth and YODM had dietary imbalances (<xref ref-type="bibr" rid="B81">81</xref>). Changes in gastric redoxin secretion may be an early biomarker of impaired glucose regulation in obese children with IR (<xref ref-type="bibr" rid="B82">82</xref>). Relevant studies found that for each additional hour of sedentary time and screen use between ages 8&#x2013;10 and 15&#x2013;17, insulin sensitivity decreased by 8.2% and 6.4%, respectively, while fasting blood glucose increased by 0.03 mmol/L and 0.02 mmol/L. This emphasized the evidence of sedentary behavior and screen time as key driving factors for the high-risk development of YODM (<xref ref-type="bibr" rid="B83">83</xref>).</p>
<p>Simultaneously, numerous factors, including genetics, inflammation and immunity, lipid metabolism, and adolescent hormones, affect signaling pathways such as insulin receptors, mediating the occurrence of IR. Firstly, certain genetic variations may lead to IR during adolescence. Studies indicate that polymorphisms in specific genes may influence key molecules in insulin signal transduction pathways, resulting in the occurrence of IR. The development of IR in YODM usually involves complex regulation by various genetic mechanisms. Genes of the insulin receptor substrate (IRS) family are closely associated with IR. Proteins encoded by IRS genes are critical molecules in insulin signal transduction pathways, and their abnormal function may lead to IR. Polymorphisms in IRS genes have been found to be associated with the development of IR in YODM.</p>
<p>Polymorphisms in inflammatory factor genes may be associated with IR in YODM. Chronic inflammation associated with obesity can lead to IR and &#x3b2;-cell dysfunction (<xref ref-type="bibr" rid="B84">84</xref>). Abnormal expression of inflammatory factors may increase tissue inflammatory responses, thereby interfering with the normal function of insulin signal pathways, leading to IR. During adolescence, changes in hormone levels and cytokines may increase adipose tissue inflammatory responses, further exacerbating the degree of IR. Inflammatory responses lead to increased release of cytokines such as tumor necrosis factor-alpha (TNF-&#x3b1;) and interleukin-6 (IL-6). These cytokines may directly interfere with insulin signal transduction pathways, affecting the function of insulin receptors and the effectiveness of insulin. The pro-inflammatory cytokine TNF-&#x3b1; can induce IR by disrupting early insulin-stimulated tyrosine phosphorylation (<xref ref-type="bibr" rid="B85">85</xref>). The increase in inflammatory reactions may induce autoimmune reactions, activate immune cells, disrupt immune regulation, and cause immune stress, leading to increased release of inflammatory factors, thus interfering with the normal function of insulin signal pathways. Activation of autoimmune reactions may damage and destroy insulin-secreting cells. Activation of immune cells such as macrophages and lymphocytes may increase the release of inflammatory factors, affecting the normal function of insulin signal pathways. Imbalance in immune regulation may lead to an increase in inflammatory reactions and abnormal activation of immune cells. Chronic immune stress may lead to increased activation of immune cells and increased release of inflammatory factors. All these abnormal changes can affect the normal function of insulin signal pathways.</p>
<p>Patients with YODM often exhibit lipid metabolism disorders (<xref ref-type="bibr" rid="B86">86</xref>, <xref ref-type="bibr" rid="B87">87</xref>), including hyperinsulinemia and lipid peroxidation. These factors lead to the release of more fatty acids from adipocytes, further worsening IR and insufficient insulin secretion. IR can also lead to abnormalities in lipid metabolism, where fatty acids are not efficiently utilized by muscle and adipose tissues, leading to the synthesis of triglycerides in the liver, resulting in a vicious cycle of fatty liver and IR. The main cause of lipid metabolism disorders may be attributed to poor lifestyle habits during adolescence. A high-sugar, high-fat, high-energy-density diet may lead to weight gain and fat accumulation. Additionally, poor dietary structure may lead to abnormal expression of key molecules in the insulin signal pathway, thereby disrupting normal insulin signal transduction. Lack of physical exercise leads to reduced energy consumption in muscles, lipid metabolism disorders, and decreased insulin sensitivity. Moderate physical exercise helps control weight, improve the function of insulin signal pathways, and thus alleviate the degree of IR. Mechanistically, adipose tissue secretes various factors, including leptin, adiponectin, etc., which may negatively impact insulin sensitivity. The IR in YODM is related to the total body fat mass, especially visceral fat. This is mediated by various fat factors, including leptin, resistin, interleukin-6 (IL-6), and tumor necrosis factor-alpha (TNF-&#x3b1;). Additionally, non-esterified fatty acids contribute to IR by increasing hepatic glucose output and hindering glucose uptake in skeletal muscles (<xref ref-type="bibr" rid="B88">88</xref>, <xref ref-type="bibr" rid="B89">89</xref>). Furthermore, an increase in visceral fat leads to decreased levels of adiponectin and reduced expression of adiponectin receptors on cell surfaces (<xref ref-type="bibr" rid="B90">90</xref>).</p>
<p>Adolescence is a critical period for growth and development, and changes in hormone levels during puberty have a significant impact on insulin sensitivity. During adolescence, changes in sex hormones may affect fat distribution and the growth and development of muscle tissue, influencing the function of insulin signal transduction pathways. Alternatively, hormonal changes during adolescence may affect IR through neuroendocrine regulatory mechanisms. Other factors, including changes in thyroid hormone levels and adrenal cortex hormone levels during adolescence, may also affect metabolic pathways and insulin signal transduction, thereby influencing the occurrence of IR.</p>
</sec>
</sec>
<sec id="s4">
<label>4</label>
<title>Comprehensive management strategies for YODM from the perspective of IR</title>
<p>In 2016, the WHO&#x2019;s &#x201c;Global Diabetes Report&#x201d; clearly stated that weight loss and restricted energy intake could lead to the remission of T2DM. In 2021, the ADA defined T2DM, recommending discontinuation of antidiabetic medications for at least 3 months, with a glycated hemoglobin (HbA1c) &lt; 6.5% as the standard for T2DM remission. However, in certain situations, such as the presence of hemoglobin variants, diseases affecting red blood cell lifespan, or inaccuracies in HbA1c testing methods, HbA1c may not reflect true blood glucose levels. In such cases, FBG &lt; 7.0 mmol/L or estimated HbA1c &lt; 6.5% through continuous glucose monitoring (CGM) can be used as alternative criteria. There is clear clinical evidence supporting the significant reduction in weight and promotion of T2DM remission through enhanced lifestyle interventions or metabolic surgery in T2DM patients with a short course and obesity (<xref ref-type="bibr" rid="B91">91</xref>, <xref ref-type="bibr" rid="B92">92</xref>). Additionally, short-term insulin therapy in newly diagnosed T2DM patients has also been shown to promote T2DM remission (<xref ref-type="bibr" rid="B93">93</xref>). While this evidence is focused on adults, it suggests that early intervention, including weight loss or medication targeting obesity, may be a crucial strategy for YODM to achieve diabetes remission (<xref ref-type="bibr" rid="B94">94</xref>). Therefore, early intervention strategies targeting IR, as a key factor in the occurrence and development of YODM, are crucial for achieving diabetes remission, with a focus on weight loss (<xref ref-type="bibr" rid="B95">95</xref>). Chronic hyperglycemia, or T2DM itself, is a significant cause of macrovascular and microvascular complications, including cardiovascular events, renal failure, and diabetes-related established microvascular and macrovascular damage leading to vision loss (<xref ref-type="bibr" rid="B96">96</xref>, <xref ref-type="bibr" rid="B97">97</xref>). The remission of T2DM is associated with a lower risk of microvascular complications, especially in younger populations (under 45 years old) and those with fewer complications (none or less than 3) (<xref ref-type="bibr" rid="B98">98</xref>). Diabetes remission significantly helps improve patients&#x2019; quality of life and reduce the risk of complications. Therefore, the management strategy for YODM should shift some focus from controlling blood glucose and preventing complications to relieving diabetes. This should be the ideal treatment goal for such patients: early identification, early disease detection, precise screening of patients with well-functioning insulin beta cells, IR as the main pathological change, and obesity. This group is most likely to achieve diabetes remission or reversal through measures such as lifestyle changes, medication, or even surgery. Furthermore, considering that this population may have more emotional disorders or hormonal influences during adolescence, it is essential to provide health education to patients and caregivers, making them aware of the long-term benefits of maintaining good blood sugar control. In summary, the ideal goal is to adopt comprehensive measures to achieve diabetes remission or reversal, followed by controlling high blood sugar, obesity, and other risk factors associated with diabetes complications to delay the occurrence and progression of complications (<xref ref-type="fig" rid="f2">
<bold>Figure&#xa0;2</bold>
</xref>).</p>
<fig id="f2" position="float">
<label>Figure&#xa0;2</label>
<caption>
<p>Comprehensive management strategies for YODM from the perspective of IR.</p>
</caption>
<graphic mimetype="image" mime-subtype="tiff" xlink:href="fendo-15-1377918-g002.tif"/>
</fig>
<sec id="s4_1">
<label>4.1</label>
<title>YODM patients experience faster disease progression, emphasizing the importance of early identification and early intervention</title>
<p>Early diagnosis and intervention help control the progression of the disease. In the early stages of diabetes diagnosis, effective treatment measures can improve the patient&#x2019;s condition and contribute to diabetes remission. Approximately 40% of YODM cases are asymptomatic at the time of diagnosis, as diabetes is detected through screening due to signs of obesity, other risk factors, or IR (<xref ref-type="bibr" rid="B99">99</xref>). Therefore, early identification is crucial and can be achieved through alternative indicators such as waist circumference, triglyceride-glucose (TyG) index, metabolites, and IR index.</p>
<p>A study analyzing data from 38,000 Brazilian adolescents aged 12 to 17 compared the associations between obesity, overweight, waist circumference, and IR. The results showed that waist circumference is more helpful in identifying adolescents with IR, especially in late adolescence (<xref ref-type="bibr" rid="B100">100</xref>). Another multicenter cross-sectional study analyzed 161 newly diagnosed T2DM children and adolescents, with 1,935 children with normal blood sugar as healthy controls. The results indicated that the increase in HOMA2-B and HOMA2-IR is associated with a higher risk of T2DM, suggesting that besides IR, impaired beta-cell function is closely related to Chinese YODM. Gender differences in susceptibility and higher complications require YODM screening and prevention strategies (<xref ref-type="bibr" rid="B101">101</xref>). The triglyceride-glucose (TyG) index [area under the curve (AUC) 0.839)] showed better performance in identifying T2DM patients than HOMA-IR (AUC 0.645), demonstrating a significant association between IR and T2DM (<xref ref-type="bibr" rid="B102">102</xref>). Respiratory metabolites, including limonene, nonane, and 2,7-dimethylundecane, are correlated with IR evaluated by the homeostasis model assessment (HOMA-IR). Given their simple and non-invasive breath-based testing, these substances have the potential to serve as effective measures for early detection of insulin resistance (<xref ref-type="bibr" rid="B103">103</xref>). Another study tracking 190 newly diagnosed T2DM patients for 5 years identified 12 different metabolites, with forty-two hexaenoic acid, oxygen tri-nucleotide, dihydrocholesterol, and trienoic acid being the most representative (<xref ref-type="bibr" rid="B104">104</xref>).</p>
<p>In recent years, the global prevalence of T2DM has been increasing annually, with a significant contributing factor being the rising rates of overweight or obesity due to lifestyle changes. Clinical research results indicate that whether through lifestyle, medication, or metabolic surgical interventions, it is possible to slow down the progression from prediabetes to diabetes or achieve the reversal of elevated blood sugar, leading to normal levels, as T2DM remission (<xref ref-type="bibr" rid="B105">105</xref>, <xref ref-type="bibr" rid="B106">106</xref>). Current research indicates that only some patients can achieve diabetes remission. These conditions include the exclusion of specific types of diabetes, such as secondary diabetes or diabetes caused by certain genetic factors, as well as patients with a longer course, more severe complications, and poor pancreatic beta-cell function. For T2DM patients without autoimmune destruction of pancreatic islets, overweight or obesity (BMI &#x2265; 25 kg/m<sup>2</sup>), preserved beta-cell function, and a course of &#x2264; 5 years have a higher likelihood of remission (<xref ref-type="bibr" rid="B91">91</xref>, <xref ref-type="bibr" rid="B107">107</xref>). However, among these conditions, early-stage obesity serves as a crucial signal for achieving diabetes remission.</p>
<p>The Japan Diabetes Data Management (JDDM74) analyzed data from over 4,000 patients over 30 years nationwide, with 3,454 patients achieving diabetes remission, significantly correlated with a moderate weight loss of 3.0&#x2013;7.9% (<xref ref-type="bibr" rid="B108">108</xref>). Therefore, based on the current clinical characteristics achievable for diabetic patients, combined with ongoing interventional research, weight loss and subsequent visceral fat loss are crucial for relieving T2DM, with obesity being the central core for achieving remission. Obesity can lead to excessive growth of adipose tissue, especially abdominal fat. This adipose tissue releases various hormones and cytokines, including free fatty acids, leptin, tumor necrosis factor, etc. These substances can interfere with insulin signaling, leading to insulin resistance. In the obese population, adipose tissue releases an increasing amount of non-esterified fatty acids, glycerol, hormones, pro-inflammatory cytokines, and other factors involved in the development of insulin resistance (<xref ref-type="bibr" rid="B109">109</xref>).</p>
</sec>
<sec id="s4_2">
<label>4.2</label>
<title>Poor adherence in YODM patients: cultivating effective self-management and improving adherence are key to diabetes management</title>
<p>Unlike adults, adolescents are more heavily influenced by external factors, making it challenging for many YODM patients to effectively control their diet, engage in physical activity, and manage blood glucose in their daily lives. Adolescents, being in a sensitive period of growth transition, often experience unstable behavioral and emotional states, hindering stable blood sugar control. However, the remission of diabetes may have more significant benefits for adolescents. Medical goals for YODM include preventing further weight gain and/or achieving weight loss (encouraging obese patients to lose 7&#x2013;10% of their weight), maintaining good blood sugar control, reducing disease-related stress, and managing adolescent psychosocial issues (<xref ref-type="bibr" rid="B110">110</xref>).</p>
<p>For diabetes patients, especially adolescents, considerations should extend beyond the treatment of diabetes itself to include other conditions caused by diabetes, including the emotional disorders often associated with adolescents. Diabetes distress encompasses complications, self-management demands, unresponsive provider reactions, poor interpersonal relationships, and negative emotional responses to diabetes itself. Depression and diabetes distress screening scores are closely related to YODM, similar to adolescents with T1DM (<xref ref-type="bibr" rid="B111">111</xref>). YODM exposed to various stressful life events often experience reduced quality of life, depressive symptoms, and lower compliance with prescription oral medications (<xref ref-type="bibr" rid="B112">112</xref>). In the Pediatric Diabetes Consortium, 22% of YODM cases were found to have comorbid depression, with only 9% receiving treatment in the past 12 months (<xref ref-type="bibr" rid="B113">113</xref>). Compared to non-diabetic peers, YODM is more likely to experience emotional or anxiety disorders before and after diagnosis (<xref ref-type="bibr" rid="B114">114</xref>). Therefore, patients must possess good self-management skills, adhere to dietary controls, medication regimens, and regularly monitor blood glucose levels. Patients should comply with treatment plans, including regular medication intake, follow-up appointments, and actively collaborate with doctors in adjusting and improving treatment plans.</p>
</sec>
<sec id="s4_3">
<label>4.3</label>
<title>IR and obesity: reciprocal causation, choosing appropriate weight loss methods is a crucial means of improving IR and achieving diabetes remission</title>
<p>Controlling body weight, especially for obese diabetes patients, can improve insulin sensitivity, contributing to the remission of diabetes. Therefore, weight loss and subsequent reduction in visceral fat are key to diabetes remission (<xref ref-type="bibr" rid="B115">115</xref>). Compared to adolescents, pre-adolescent YODM patients face a higher risk of related incidence, emphasizing the importance of intervention measures to prevent and treat obesity in early childhood (<xref ref-type="bibr" rid="B116">116</xref>). Patients need to adhere to a healthy lifestyle, including regular physical exercise, maintaining healthy dietary habits, and avoiding unhealthy habits such as smoking and excessive alcohol consumption. The Population-based Panasonic cohort study in Japan, analyzing the relationship between changes and diabetes remission in 1,903 patients over a 5-year period, showed that weight loss of &#x2265;3.9 kg or &#x2265;5.0% in patients with BMI &#x2265; 25 kg/m<sup>2</sup> (obesity) may be effective in relieving new-onset type 2 diabetes, excluding patients with BMI &lt; 25 kg/m<sup>2</sup> (<xref ref-type="bibr" rid="B117">117</xref>). Lifestyle changes are an important component of YODM weight management. The T2DM youth weight management guidelines recommend that adolescents reach at least a 7&#x2013;10% weight reduction from their final adult height, with weight indexes below the 85th percentile for those still growing (<xref ref-type="bibr" rid="B118">118</xref>) (<xref ref-type="table" rid="T1">
<bold>Table&#xa0;1</bold>
</xref>).</p>
<table-wrap id="T1" position="float">
<label>Table&#xa0;1</label>
<caption>
<p>Potential beneficial management strategies for YODM.</p>
</caption>
<table frame="hsides">
<thead>
<tr>
<th valign="top" align="left">Management Strategies</th>
<th valign="top" align="center">Contents</th>
</tr>
</thead>
<tbody>
<tr>
<th valign="top" colspan="2" align="left">Dietary Management</th>
</tr>
<tr>
<td valign="top" align="left">&#x2003;Intermittent Fasting</td>
<td valign="top" align="left">Alternate-Day Fasting, 5:2 Diet, 16:8 Diet, Random Fasting</td>
</tr>
<tr>
<td valign="top" align="left">&#x2003;Low-Energy Diet</td>
<td valign="top" align="left">Daily intake of 800&#x2013;1500 kcal; prioritize low-energy density foods; reduce intake of high-energy density foods; avoid sugary beverages; ensure adequate intake of protein, fiber, vitamins, and minerals to prevent malnutrition.</td>
</tr>
<tr>
<td valign="top" align="left">&#x2003;Low-carbohydrate Diet</td>
<td valign="top" align="left">Daily carbohydrate intake is typically kept between 20&#x2013;100 grams, with specific amounts varying from person to person; increase intake of protein and healthy fats; choose low-carbohydrate vegetables; avoid high-sugar fruits, grains, starchy vegetables, and refined carbohydrates.</td>
</tr>
<tr>
<td valign="top" align="left">&#x2003;Mediterranean Diet</td>
<td valign="top" align="left">The main foods include plenty of fruits, vegetables, whole grains, legumes, nuts, and seeds; healthy fats primarily sourced from olive oil, nuts, and seeds; protein mainly from fish and seafood, moderate amounts of poultry, eggs, and dairy, with red meat and processed meats limited; moderate intake of low-fat dairy products; moderate consumption of red wine (optional), with water as the primary beverage; using herbs and spices instead of salt for seasoning; encouraging communal dining with family and friends to enjoy the mealtime experience.</td>
</tr>
<tr>
<td valign="top" align="left">
<bold>&#x2003;Exercise Methods</bold>
</td>
<td valign="top" align="left">Engage in moderate to vigorous physical activity for 30 to 60 minutes on 3 days per week.</td>
</tr>
<tr>
<th valign="top" colspan="2" align="left">Medication Therapy</th>
</tr>
<tr>
<td valign="top" align="left">&#x2003;Insulin</td>
<td valign="top" align="left">Glargine; Getemir; Degludec</td>
</tr>
<tr>
<td valign="top" align="left">&#x2003;Biguanides</td>
<td valign="top" align="left">Metformin</td>
</tr>
<tr>
<td valign="top" align="left">&#x2003;GLP-1RA</td>
<td valign="top" align="left">Liraglutide; Dulaglutide; Exenatide</td>
</tr>
<tr>
<td valign="top" align="left">&#x2003;Sulfonylureas</td>
<td valign="top" align="left">Glimepiride; Glipizide; Glyburide</td>
</tr>
<tr>
<td valign="top" align="left">&#x2003;SGLT-2i</td>
<td valign="top" align="left">Dapagliflozin</td>
</tr>
<tr>
<td valign="top" align="left">&#x2003;DPP-4 Inhibitors</td>
<td valign="top" align="left">Sitagliptin, Linagliptin</td>
</tr>
<tr>
<td valign="top" align="left">
<bold>Weight Loss Surgery</bold>
</td>
<td valign="top" align="left">Laparoscopic Sleeve Gastrectomy; Roux-en-Y Gastric Bypass</td>
</tr>
</tbody>
</table>
</table-wrap>
<p>While there is currently evidence supporting the effectiveness of certain treatments in adolescents with type 2 diabetes, we must also be mindful of the potential side effects associated with these treatments (<xref ref-type="bibr" rid="B119">119</xref>). These include the possibility of hypoglycemic reactions, gastrointestinal discomfort, drug allergies, and others. Additionally, weight-loss surgery may lead to postoperative malnutrition, gastric emptying disorders, abnormal insulin secretion, among other issues (<xref ref-type="bibr" rid="B120">120</xref>, <xref ref-type="bibr" rid="B121">121</xref>). Considering the psychological sensitivity of patients, it is crucial to continuously monitor their psychological status when implementing treatment plans or making recommendations. Timely intervention for any emerging social and psychological barriers is also necessary.</p>
<sec id="s4_3_1">
<label>4.3.1</label>
<title>Dietary therapy</title>
<p>Dietary control can achieve standard weight and correct metabolic disorders. Dietary fiber can improve postprandial blood sugar and long-term diabetes control, with grain dietary fiber enhancing insulin sensitivity. As part of intensified lifestyle therapy, every T2DM patient should undergo comprehensive nutritional education (<xref ref-type="bibr" rid="B122">122</xref>). Reducing the consumption of sugary beverages, increasing the consumption of whole-grain bread and cereals, fruits, and vegetables is recommended (<xref ref-type="bibr" rid="B123">123</xref>). A randomized controlled clinical study in China confirmed that intermittent fasting intervention for 3 months could achieve diabetes remission for at least a year (<xref ref-type="bibr" rid="B124">124</xref>). A systematic review evaluating lifestyle changes (including three types of diets&#x2014;low-energy diet, low-carbohydrate diet, Mediterranean diet, and exercise including aerobic and resistance sports, walking, and maintaining habitual physical activity) demonstrated effective diabetes remission, including weight loss and improved quality of life (<xref ref-type="bibr" rid="B125">125</xref>).</p>
</sec>
<sec id="s4_3_2">
<label>4.3.2</label>
<title>Exercise therapy</title>
<p>Exercise plays a crucial role in the treatment of YODM, aiding in weight reduction, increasing insulin sensitivity, and enhancing peripheral tissue glucose uptake. The choice of exercise type and amount should be individualized based on gender, age, physique, physical strength, exercise habits, and preferences. Clear evidence indicates that regular physical activity benefits children and adolescents, including developing motor skills, promoting healthy weight and body composition, supporting bone and muscle development, and positively influencing insulin sensitivity (<xref ref-type="bibr" rid="B126">126</xref>, <xref ref-type="bibr" rid="B127">127</xref>). Engaging in vigorous physical activity for 16 weeks twice a week significantly increased insulin sensitivity in overweight adolescents, independent of changes in total fat mass and lean tissue mass (<xref ref-type="bibr" rid="B128">128</xref>). The American Diabetes Association (ADA) and the International Society for Pediatric and Adolescent Diabetes (ISPAD) recommend encouraging adolescents with Youth-Onset Diabetes Mellitus (YODM) to engage in at least 60 minutes of moderate to vigorous physical activity daily, including muscle and bone strength training at least 3 days per week (<xref ref-type="bibr" rid="B129">129</xref>, <xref ref-type="bibr" rid="B130">130</xref>). Exercise increases the expression of GLUT4 receptors, thereby enhancing peripheral glucose absorption. The benefits of improved insulin sensitivity persist for 16 hours after exercise in both healthy subjects and patients with Type 2 Diabetes Mellitus (T2DM) (<xref ref-type="bibr" rid="B131">131</xref>). In a cross-sectional study involving 164 YODM adolescents engaging in vigorous physical activity, lower HbA1c levels and better cardiovascular parameters were observed (<xref ref-type="bibr" rid="B132">132</xref>).</p>
</sec>
<sec id="s4_3_3">
<label>4.3.3</label>
<title>Pharmacological treatment</title>
<p>Despite significant progress in the treatment of adult T2DM over the past few decades, the efficacy in YODM has seen only slight changes. Besides insulin, metformin is the first-line medication approved by the U.S. Food and Drug Administration (FDA) for treating YODM (<xref ref-type="bibr" rid="B118">118</xref>, <xref ref-type="bibr" rid="B133">133</xref>). Although emerging therapies have provided new perspectives for managing YODM, metformin remains a cost-effective and safe part of treatment plans for many YODM patients globally due to its beneficial metabolic effects (<xref ref-type="bibr" rid="B134">134</xref>). However, the reality reflects that in almost half of the cases, metformin has been found insufficient for treating YODM (<xref ref-type="bibr" rid="B135">135</xref>, <xref ref-type="bibr" rid="B136">136</xref>), especially in adolescents with severe metabolic disturbances at the time of diagnosis (<xref ref-type="bibr" rid="B137">137</xref>). Given that postprandial insulin release is often blunted or impaired in T2DM patients, GLP-1 agonists improve blood glucose control by enhancing postprandial insulin release. Additionally, these drugs slow gastric emptying, prolong beta-cell lifespan by inhibiting apoptosis, increase peripheral glucose uptake in muscles, and reduce hepatic glucose output, thereby improving insulin sensitivity. An indirect mechanism for improving insulin sensitivity is weight loss. The weight-loss effects of these drugs are primarily attributed to delayed gastric emptying and direct effects on suppressing appetite in the hypothalamus (<xref ref-type="bibr" rid="B138">138</xref>, <xref ref-type="bibr" rid="B139">139</xref>). Compared to liraglutide, semaglutide has shown promising weight-loss effects in adults with obesity and T2DM (<xref ref-type="bibr" rid="B140">140</xref>, <xref ref-type="bibr" rid="B141">141</xref>). Until July 2019, the GLP-1 receptor agonist liraglutide was approved by the FDA for treating YODM and/or obesity in individuals aged 10 and above (<xref ref-type="bibr" rid="B142">142</xref>, <xref ref-type="bibr" rid="B143">143</xref>). However, the approved dose for weight management (3 mg per day) is higher than the dose used for managing T2DM (1.8 mg per day). In a systematic review of 9 randomized controlled trials involving 286 obese, prediabetic, or YODM individuals aged 18 and under, GLP-1 agonist use was associated with an average weight loss of 2.7 kg. This effect was observed more in patients with higher BMI (<xref ref-type="bibr" rid="B144">144</xref>). A randomized controlled trial showed a favorable impact on YODM weight when GLP-1 agonists were used in conjunction with metformin. In a study of 134 children and adolescents (10&#x2013;17 years) with T2DM, the liraglutide group experienced a weight loss of 2.3 kg at week 26, while the placebo group lost 0.99 kg (<xref ref-type="bibr" rid="B145">145</xref>). An investigation in Korea assessed the efficacy and side effects of once-weekly dulaglutide in treating YODM. The results indicated excellent glycemic control with once-weekly dulaglutide for YODM, with no significant side effects (<xref ref-type="bibr" rid="B146">146</xref>). However, other studies found additional side effects of GLP-1 agonists, including vomiting, diarrhea, abdominal pain, hypoglycemia, elevated transaminases, and pancreatitis (<xref ref-type="bibr" rid="B147">147</xref>). The use of sulfonylurea drugs in children effectively lowers HbA1c by 1.5&#x2013;2% and has been approved in several countries. However, adverse reactions, including weight gain, accelerated &#x3b2;-cell loss, and hypoglycemia leading to seizures and negative cognitive consequences, have been observed (<xref ref-type="bibr" rid="B148">148</xref>). An evaluation of the efficacy and safety of several glucose-lowering medications provides additional options for YODM management. Compared to FDA-approved drugs, dapagliflozin, sitagliptin+metformin, and saxagliptin+metformin showed better efficacy, indicating the top ten treatment methods for YODM in individuals aged 10&#x2013;17: saxagliptin+metformin, liraglutide+metformin, liraglutide, dapagliflozin, exenatide-2 mcg, sitagliptin+metformin, linagliptin-5 mg, linagliptin-1 mg, metformin, and exenatide-5/10 mcg (<xref ref-type="bibr" rid="B149">149</xref>).</p>
<p>Implementing short-term intensified insulin therapy in uncontrolled hyperglycemic patients in the early stages of the disease improves &#x3b2;-cell function, ensuring remission of T2DM for a considerable period (<xref ref-type="bibr" rid="B150">150</xref>, <xref ref-type="bibr" rid="B151">151</xref>). Insulin therapy is typically associated with weight gain (<xref ref-type="bibr" rid="B152">152</xref>, <xref ref-type="bibr" rid="B153">153</xref>). Remission after intensified insulin therapy has been shown to last for over 2 years, and the shorter the time interval between diagnosis and intensified insulin therapy, the greater the likelihood of remission (<xref ref-type="bibr" rid="B154">154</xref>). According to the International Society for Pediatric and Adolescent Diabetes (ISPAD) guidelines, if HbA1c levels do not reach the target of 6.5&#x2013;7% after 4 months of metformin treatment for YODM, initiating basal insulin at a dose of 1.5 IU/kg/day is recommended. If adding basal insulin is insufficient, prandial insulin at a dose of 0.1 U/kg/meal may be necessary (<xref ref-type="bibr" rid="B148">148</xref>).</p>
</sec>
<sec id="s4_3_4">
<label>4.3.4</label>
<title>Bariatric surgical treatment</title>
<p>For patients who find it challenging to achieve weight loss after lifestyle interventions, or for those who prefer a more direct approach, bariatric surgery can be considered. The American Diabetes Association (ADA) recommends considering bariatric surgery for YODM patients with a BMI greater than 35 kg/m<sup>2</sup>, as surgery has a more favorable impact on blood glucose control (including HBG, HbA1c, HOMA-IR) compared to medical treatments (<xref ref-type="bibr" rid="B155">155</xref>). Metabolic and bariatric surgery (MBS) has been associated with excellent weight loss and T2DM remission in adolescents (<xref ref-type="bibr" rid="B156">156</xref>, <xref ref-type="bibr" rid="B157">157</xref>). The two most common surgeries for adolescents are laparoscopic sleeve gastrectomy (LSG) and Roux-en-Y gastric bypass. In the TEEN-LABS alliance study, among 242 adolescents undergoing MBS, the average weight decreased by 27% three years after surgical intervention. There was no significant difference in weight loss between patients undergoing Roux-en-Y gastric bypass (161 participants) or sleeve gastrectomy (67 participants) (28% and 26%, respectively). Furthermore, 95% (95% CI; 85 to 100) of patients with T2DM at the time of surgery achieved remission. Similarly, remission rates for other comorbidities were high (renal dysfunction at 86%, prediabetes at 76%, hypertension at 74%, dyslipidemia at 66%) (<xref ref-type="bibr" rid="B120">120</xref>). Laparoscopic sleeve gastrectomy (LSG) is gradually becoming a new benchmark for the treatment of morbid obesity and related complications in pediatric cases. A retrospective study involving 64 pediatric patients aged 5 to 14 provided further specific evidence of the beneficial metabolic effects of LSG surgery on morbidly obese children, effectively reducing complications related to Type 2 diabetes by lowering HbA1c levels after surgery (<xref ref-type="bibr" rid="B158">158</xref>).</p>
</sec>
</sec>
</sec>
<sec id="s5">
<label>5</label>
<title>Outlook and conclusion</title>
<p>Overall, based on the existing published research, there are still many areas that need improvement in screening, treatment, and other aspects of YODM. Given the continuously increasing number of YODM patients and the limited interventions available, there is a need to focus more on key aspects of the occurrence and development of YODM. This includes early identification and timely intervention, considering the unique characteristics of adolescents. For early identification, constructing predictive models that encompass various risk factors such as obesity, family history, unhealthy lifestyle habits, emotional disorders, along with data from metabolic and insulin resistance testing, may help identify patients early on. Specifically, in the future, leveraging new technologies such as artificial intelligence, big data, and others can provide more intelligent and precise support for early screening, diagnosis, and treatment of type 2 diabetes in adolescents. It is crucial not to wait until other chronic complications (such as peripheral neuropathy, kidney disease) or acute complications (such as ketoacidosis) emerge. Early intervention during this golden period is essential for achieving diabetes remission. In the future, precision medicine approaches such as genomics and metabolomics can be utilized to provide more personalized diagnosis and treatment for type 2 diabetes in adolescents, thereby improving treatment effectiveness and prognosis. Currently, the key interventions for diabetes patients consistently revolve around insulin resistance-mediated obesity, emphasizing the importance of maintaining normal weight. Good lifestyle habits are crucial in this regard and require supervision and monitoring from family and schools. Indeed, strengthening health education and intervention strategies across multiple levels such as family, school, and community can promote the adoption of healthy lifestyles among adolescents, thereby preventing and controlling the occurrence and progression of type 2 diabetes. Medications such as GLP-1 agonists can serve as effective supplementary interventions. For some patients, bariatric surgery may be more suitable and effective. Of course, in the future, precision medicine approaches such as genomics and metabolomics can be utilized to provide more personalized diagnosis and treatment for type 2 diabetes in adolescents, thereby improving treatment effectiveness and prognosis.</p>
<p>In summary, early identification, early intervention, and effective evaluation centered around IR in YODM can be crucial for achieving diabetes remission. However, healthcare professionals and researchers may significantly help individuals with YODM by identifying and implementing better strategies for improving insulin resistance and intervening in obesity at an early stage.</p>
</sec>
<sec id="s6" sec-type="author-contributions">
<title>Author contributions</title>
<p>QJ: Writing &#x2013; original draft, Writing &#x2013; review &amp; editing. YZ: Writing &#x2013; original draft. BZ: Conceptualization, Writing &#x2013; review &amp; editing. XA: Conceptualization, Writing &#x2013; original draft, Writing &#x2013; review &amp; editing.</p>
</sec>
</body>
<back>
<sec id="s7" sec-type="funding-information">
<title>Funding</title>
<p>The author(s) declare financial support was received for the research, authorship, and/or publication of this article. This study was supported by the National Natural Science Foundation of China (82305205), High Level Chinese Medical Hospital Promotion Project (HLCMHPP2023084), Youth Talent Support Project of the Chinese Association of Chinese Medicine (CACM-2023-QNRC2-A05).</p>
</sec>
<sec id="s8" sec-type="COI-statement">
<title>Conflict of interest</title>
<p>The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.</p>
</sec>
<sec id="s9" sec-type="disclaimer">
<title>Publisher&#x2019;s note</title>
<p>All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.</p>
</sec>
<ref-list>
<title>References</title>
<ref id="B1">
<label>1</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Wang</surname> <given-names>J</given-names>
</name>
<name>
<surname>Wu</surname> <given-names>W</given-names>
</name>
<name>
<surname>Dong</surname> <given-names>G</given-names>
</name>
<name>
<surname>Huang</surname> <given-names>K</given-names>
</name>
<name>
<surname>Fu</surname> <given-names>J</given-names>
</name>
</person-group>. <article-title>Pediatric diabetes in China: Challenges and actions</article-title>. <source>Pediatr Diabetes</source>. (<year>2022</year>) <volume>23</volume>:<page-range>545&#x2013;50</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1111/pedi.13344</pub-id>
</citation>
</ref>
<ref id="B2">
<label>2</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Wu</surname> <given-names>H</given-names>
</name>
<name>
<surname>Patterson</surname> <given-names>CC</given-names>
</name>
<name>
<surname>Zhang</surname> <given-names>X</given-names>
</name>
<name>
<surname>Ghani</surname> <given-names>RBA</given-names>
</name>
<name>
<surname>Magliano</surname> <given-names>DJ</given-names>
</name>
<name>
<surname>Boyko</surname> <given-names>EJ</given-names>
</name>
<etal/>
</person-group>. <article-title>Worldwide estimates of incidence of type 2 diabetes in children and adolescents in 2021</article-title>. <source>Diabetes Res Clin Pract</source>. (<year>2022</year>) <volume>185</volume>:<fpage>109785</fpage>. doi:&#xa0;<pub-id pub-id-type="doi">10.1016/j.diabres.2022.109785</pub-id>
</citation>
</ref>
<ref id="B3">
<label>3</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Mayer-Davis</surname> <given-names>EJ</given-names>
</name>
<name>
<surname>Lawrence</surname> <given-names>JM</given-names>
</name>
<name>
<surname>Dabelea</surname> <given-names>D</given-names>
</name>
<name>
<surname>Divers</surname> <given-names>J</given-names>
</name>
<name>
<surname>Isom</surname> <given-names>S</given-names>
</name>
<name>
<surname>Dolan</surname> <given-names>L</given-names>
</name>
<etal/>
</person-group>. <article-title>Incidence trends of type 1 and type 2 diabetes among youths, 2002&#x2013;2012</article-title>. <source>N Engl J Med</source>. (<year>2017</year>) <volume>376</volume>:<page-range>1419&#x2013;29</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1056/NEJMoa1610187</pub-id>
</citation>
</ref>
<ref id="B4">
<label>4</label>
<citation citation-type="book">
<person-group person-group-type="author">
<collab>U.S. Department of Health and Human Services</collab>
</person-group>. <source>Healthy people</source>. <publisher-loc>Washington, DC</publisher-loc> (<year>2020</year>). Available at: <uri xlink:href="http://www.healthypeople.gov/2020">http://www.healthypeople.gov/2020</uri>.</citation>
</ref>
<ref id="B5">
<label>5</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Wilfley</surname> <given-names>D</given-names>
</name>
<name>
<surname>Berkowitz</surname> <given-names>R</given-names>
</name>
<name>
<surname>Goebel-Fabbri</surname> <given-names>A</given-names>
</name>
<name>
<surname>Hirst</surname> <given-names>K</given-names>
</name>
<name>
<surname>Ievers-Landis</surname> <given-names>C</given-names>
</name>
<name>
<surname>Lipman</surname> <given-names>TH</given-names>
</name>
<etal/>
</person-group>. <article-title>Binge eating, mood, and quality of life in youth with type 2 diabetes: baseline data from the today study</article-title>. <source>Diabetes Care</source>. (<year>2011</year>) <volume>34</volume>:<page-range>858&#x2013;60</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.2337/dc10-1704</pub-id>
</citation>
</ref>
<ref id="B6">
<label>6</label>
<citation citation-type="journal">
<article-title>Type 2 diabetes in children and adolescents</article-title>. <source>Am Diabetes Assoc Diabetes Care</source>. (<year>2000</year>) <volume>23</volume>:<page-range>381&#x2013;9</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.2337/diacare.23.3.381</pub-id>
</citation>
</ref>
<ref id="B7">
<label>7</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Gulley</surname> <given-names>LD</given-names>
</name>
<name>
<surname>Shomaker</surname> <given-names>LB</given-names>
</name>
</person-group>. <article-title>Depression in youth-onset type 2 diabetes</article-title>. <source>Curr Diabetes Rep</source>. (<year>2020</year>) <volume>20</volume>:<fpage>51</fpage>. doi:&#xa0;<pub-id pub-id-type="doi">10.1007/s11892-020-01334-8</pub-id>
</citation>
</ref>
<ref id="B8">
<label>8</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Wang</surname> <given-names>J</given-names>
</name>
<name>
<surname>Wu</surname> <given-names>X</given-names>
</name>
<name>
<surname>Lai</surname> <given-names>W</given-names>
</name>
<name>
<surname>Long</surname> <given-names>E</given-names>
</name>
<name>
<surname>Zhang</surname> <given-names>X</given-names>
</name>
<name>
<surname>Li</surname> <given-names>W</given-names>
</name>
<etal/>
</person-group>. <article-title>Prevalence of depression and depressive symptoms among outpatients: a systematic review and meta-analysis</article-title>. <source>BMJ Open</source>. (<year>2017</year>) <volume>7</volume>:<elocation-id>e017173</elocation-id>. doi:&#xa0;<pub-id pub-id-type="doi">10.1136/bmjopen-2017-017173</pub-id>
</citation>
</ref>
<ref id="B9">
<label>9</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Semenkovich</surname> <given-names>K</given-names>
</name>
<name>
<surname>Brown</surname> <given-names>ME</given-names>
</name>
<name>
<surname>Svrakic</surname> <given-names>DM</given-names>
</name>
<name>
<surname>Lustman</surname> <given-names>PJ</given-names>
</name>
</person-group>. <article-title>Depression in type 2 diabetes mellitus: prevalence, impact, and treatment</article-title>. <source>Drugs</source>. (<year>2015</year>) <volume>75</volume>:<page-range>577&#x2013;87</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1007/s40265-015-0347-4</pub-id>
</citation>
</ref>
<ref id="B10">
<label>10</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Copeland</surname> <given-names>KC</given-names>
</name>
<name>
<surname>Zeitler</surname> <given-names>P</given-names>
</name>
<name>
<surname>Geffner</surname> <given-names>M</given-names>
</name>
<name>
<surname>Guandalini</surname> <given-names>C</given-names>
</name>
<name>
<surname>Higgins</surname> <given-names>J</given-names>
</name>
<name>
<surname>Hirst</surname> <given-names>K</given-names>
</name>
<etal/>
</person-group>. <article-title>Characteristics of adolescents and youth with recent-onset type 2 diabetes: the TODAY cohort at baseline</article-title>. <source>J Clin Endocrinol Metab</source>. (<year>2011</year>) <volume>96</volume>:<page-range>159&#x2013;67</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1210/jc.2010-1642</pub-id>
</citation>
</ref>
<ref id="B11">
<label>11</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Dabelea</surname> <given-names>D</given-names>
</name>
<name>
<surname>Stafford</surname> <given-names>JM</given-names>
</name>
<name>
<surname>Mayer-Davis</surname> <given-names>EJ</given-names>
</name>
<name>
<surname>D&#x2019;Agostino</surname> <given-names>R</given-names>
<suffix>Jr.</suffix>
</name>
<name>
<surname>Dolan</surname> <given-names>L</given-names>
</name>
<name>
<surname>Imperatore</surname> <given-names>G</given-names>
</name>
<etal/>
</person-group>. <article-title>Association of type 1 diabetes vs type 2 diabetes diagnosed during childhood and adolescence with complications during teenage years and young adulthood</article-title>. <source>Jama</source>. (<year>2017</year>) <volume>317</volume>:<page-range>825&#x2013;35</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1001/jama.2017.0686</pub-id>
</citation>
</ref>
<ref id="B12">
<label>12</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Gungor</surname> <given-names>N</given-names>
</name>
<name>
<surname>Hannon</surname> <given-names>T</given-names>
</name>
<name>
<surname>Libman</surname> <given-names>I</given-names>
</name>
<name>
<surname>Bacha</surname> <given-names>F</given-names>
</name>
<name>
<surname>Arslanian</surname> <given-names>S</given-names>
</name>
</person-group>. <article-title>Type 2 diabetes mellitus in youth: the complete picture to date</article-title>. <source>Pediatr Clin North Am</source>. (<year>2005</year>) <volume>52</volume>:<page-range>1579&#x2013;609</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1016/j.pcl.2005.07.009</pub-id>
</citation>
</ref>
<ref id="B13">
<label>13</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Menke</surname> <given-names>A</given-names>
</name>
<name>
<surname>Casagrande</surname> <given-names>S</given-names>
</name>
<name>
<surname>Cowie</surname> <given-names>CC</given-names>
</name>
</person-group>. <article-title>Prevalence of diabetes in adolescents aged 12 to 19 years in the United States, 2005&#x2013;2014</article-title>. <source>Jama</source>. (<year>2016</year>) <volume>316</volume>:<page-range>344&#x2013;5</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1001/jama.2016.8544</pub-id>
</citation>
</ref>
<ref id="B14">
<label>14</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Xie</surname> <given-names>J</given-names>
</name>
<name>
<surname>Wang</surname> <given-names>M</given-names>
</name>
<name>
<surname>Long</surname> <given-names>Z</given-names>
</name>
<name>
<surname>Ning</surname> <given-names>H</given-names>
</name>
<name>
<surname>Li</surname> <given-names>J</given-names>
</name>
<name>
<surname>Cao</surname> <given-names>Y</given-names>
</name>
<etal/>
</person-group>. <article-title>Global burden of type 2 diabetes in adolescents and young adults, 1990&#x2013;2019: systematic analysis of the Global Burden of Disease Study 2019</article-title>. <source>Bmj</source>. (<year>2022</year>) <volume>379</volume>:<elocation-id>e072385</elocation-id>. doi:&#xa0;<pub-id pub-id-type="doi">10.1136/bmj-2022-072385</pub-id>
</citation>
</ref>
<ref id="B15">
<label>15</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Utzschneider</surname> <given-names>KM</given-names>
</name>
<name>
<surname>Tripputi</surname> <given-names>MT</given-names>
</name>
<name>
<surname>Kozedub</surname> <given-names>A</given-names>
</name>
<name>
<surname>Mather</surname> <given-names>KJ</given-names>
</name>
<name>
<surname>Nadeau</surname> <given-names>KJ</given-names>
</name>
<name>
<surname>Edelstein</surname> <given-names>SL</given-names>
</name>
<etal/>
</person-group>. <article-title>&#x3b2;-cells in youth with impaired glucose tolerance or early type 2 diabetes secrete more insulin and are more responsive than in adults</article-title>. <source>Pediatr Diabetes</source>. (<year>2020</year>) <volume>21</volume>:<page-range>1421&#x2013;9</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1111/pedi.13113</pub-id>
</citation>
</ref>
<ref id="B16">
<label>16</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kahn</surname> <given-names>SE</given-names>
</name>
</person-group>. <article-title>Clinical review 135: The importance of beta-cell failure in the development and progression of type 2 diabetes</article-title>. <source>J Clin Endocrinol Metab</source>. (<year>2001</year>) <volume>86</volume>:<page-range>4047&#x2013;58</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1210/jcem.86.9.7713</pub-id>
</citation>
</ref>
<ref id="B17">
<label>17</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Weyer</surname> <given-names>C</given-names>
</name>
<name>
<surname>Bogardus</surname> <given-names>C</given-names>
</name>
<name>
<surname>Mott</surname> <given-names>DM</given-names>
</name>
<name>
<surname>Pratley</surname> <given-names>RE</given-names>
</name>
</person-group>. <article-title>The natural history of insulin secretory dysfunction and insulin resistance in the pathogenesis of type 2 diabetes mellitus</article-title>. <source>J Clin Invest</source>. (<year>1999</year>) <volume>104</volume>:<page-range>787&#x2013;94</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1172/JCI7231</pub-id>
</citation>
</ref>
<ref id="B18">
<label>18</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>McCombie</surname> <given-names>L</given-names>
</name>
<name>
<surname>Leslie</surname> <given-names>W</given-names>
</name>
<name>
<surname>Taylor</surname> <given-names>R</given-names>
</name>
<name>
<surname>Kennon</surname> <given-names>B</given-names>
</name>
<name>
<surname>Sattar</surname> <given-names>N</given-names>
</name>
<name>
<surname>Lean</surname> <given-names>MEJ</given-names>
</name>
</person-group>. <article-title>Beating type 2 diabetes into remission</article-title>. <source>Bmj</source>. (<year>2017</year>) <volume>358</volume>:<fpage>j4030</fpage>. doi:&#xa0;<pub-id pub-id-type="doi">10.1136/bmj.j4030</pub-id>
</citation>
</ref>
<ref id="B19">
<label>19</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Yang</surname> <given-names>YS</given-names>
</name>
<name>
<surname>Han</surname> <given-names>K</given-names>
</name>
<name>
<surname>Sohn</surname> <given-names>TS</given-names>
</name>
<name>
<surname>Kim</surname> <given-names>NH</given-names>
</name>
</person-group>. <article-title>Young-onset type 2 diabetes in South Korea: a review of the current status and unmet need</article-title>. <source>Korean J Intern Med</source>. (<year>2021</year>) <volume>36</volume>:<page-range>1049&#x2013;58</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.3904/kjim.2021.379</pub-id>
</citation>
</ref>
<ref id="B20">
<label>20</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Magliano</surname> <given-names>DJ</given-names>
</name>
<name>
<surname>Sacre</surname> <given-names>JW</given-names>
</name>
<name>
<surname>Harding</surname> <given-names>JL</given-names>
</name>
<name>
<surname>Gregg</surname> <given-names>EW</given-names>
</name>
<name>
<surname>Zimmet</surname> <given-names>PZ</given-names>
</name>
<name>
<surname>Shaw</surname> <given-names>JE</given-names>
</name>
</person-group>. <article-title>Young-onset type 2 diabetes mellitus - implications for morbidity and mortality</article-title>. <source>Nat Rev Endocrinol</source>. (<year>2020</year>) <volume>16</volume>:<page-range>321&#x2013;31</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1038/s41574-020-0334-z</pub-id>
</citation>
</ref>
<ref id="B21">
<label>21</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>La Grasta Sabolic</surname> <given-names>L</given-names>
</name>
<name>
<surname>Marusic</surname> <given-names>S</given-names>
</name>
<name>
<surname>Cigrovski Berkovic</surname> <given-names>M</given-names>
</name>
</person-group>. <article-title>Challenges and pitfalls of youth-onset type 2 diabetes</article-title>. <source>World J Diabetes</source>. (<year>2024</year>) <volume>15</volume>:<page-range>876&#x2013;85</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.4239/wjd.v15.i5.876</pub-id>
</citation>
</ref>
<ref id="B22">
<label>22</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Bjornstad</surname> <given-names>P</given-names>
</name>
<name>
<surname>Drews</surname> <given-names>KL</given-names>
</name>
<name>
<surname>Caprio</surname> <given-names>S</given-names>
</name>
<name>
<surname>Gubitosi-Klug</surname> <given-names>R</given-names>
</name>
<name>
<surname>Nathan</surname> <given-names>DM</given-names>
</name>
<name>
<surname>Tesfaldet</surname> <given-names>B</given-names>
</name>
<etal/>
</person-group>. <article-title>Long-term complications in youth-onset type 2 diabetes</article-title>. <source>N Engl J Med</source>. (<year>2021</year>) <volume>385</volume>:<page-range>416&#x2013;26</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1056/NEJMoa2100165</pub-id>
</citation>
</ref>
<ref id="B23">
<label>23</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Klingensmith</surname> <given-names>GJ</given-names>
</name>
<name>
<surname>Connor</surname> <given-names>CG</given-names>
</name>
<name>
<surname>Ruedy</surname> <given-names>KJ</given-names>
</name>
<name>
<surname>Beck</surname> <given-names>RW</given-names>
</name>
<name>
<surname>Kollman</surname> <given-names>C</given-names>
</name>
<name>
<surname>Haro</surname> <given-names>H</given-names>
</name>
<etal/>
</person-group>. <article-title>Presentation of youth with type 2 diabetes in the Pediatric Diabetes Consortium</article-title>. <source>Pediatr Diabetes</source>. (<year>2016</year>) <volume>17</volume>:<page-range>266&#x2013;73</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1111/pedi.2016.17.issue-4</pub-id>
</citation>
</ref>
<ref id="B24">
<label>24</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Chao</surname> <given-names>LC</given-names>
</name>
<name>
<surname>Vidmar</surname> <given-names>AP</given-names>
</name>
<name>
<surname>Georgia</surname> <given-names>S</given-names>
</name>
</person-group>. <article-title>Spike in diabetic ketoacidosis rates in pediatric type 2 diabetes during the COVID-19 pandemic</article-title>. <source>Diabetes Care</source>. (<year>2021</year>) <volume>44</volume>:<page-range>1451&#x2013;3</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.2337/dc20-2733</pub-id>
</citation>
</ref>
<ref id="B25">
<label>25</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Cramer</surname> <given-names>JA</given-names>
</name>
</person-group>. <article-title>A systematic review of adherence with medications for diabetes</article-title>. <source>Diabetes Care</source>. (<year>2004</year>) <volume>27</volume>:<page-range>1218&#x2013;24</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.2337/diacare.27.5.1218</pub-id>
</citation>
</ref>
<ref id="B26">
<label>26</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Comellas</surname> <given-names>M</given-names>
</name>
<name>
<surname>Marrero</surname> <given-names>Y</given-names>
</name>
<name>
<surname>George</surname> <given-names>F</given-names>
</name>
<name>
<surname>Matthews</surname> <given-names>L</given-names>
</name>
</person-group>. <article-title>Age and glycemic control among adults with type 2 diabetes in the United States: An assessment from the National Health and Nutrition Examination Survey (NHANES) 2013&#x2013;2014</article-title>. <source>Diabetes Metab Syndr</source>. (<year>2019</year>) <volume>13</volume>:<page-range>3069&#x2013;73</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1016/j.dsx.2019.11.004</pub-id>
</citation>
</ref>
<ref id="B27">
<label>27</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Yeung</surname> <given-names>RO</given-names>
</name>
<name>
<surname>Zhang</surname> <given-names>Y</given-names>
</name>
<name>
<surname>Luk</surname> <given-names>A</given-names>
</name>
<name>
<surname>Yang</surname> <given-names>W</given-names>
</name>
<name>
<surname>Sobrepena</surname> <given-names>L</given-names>
</name>
<name>
<surname>Yoon</surname> <given-names>KH</given-names>
</name>
<etal/>
</person-group>. <article-title>Metabolic profiles and treatment gaps in young-onset type 2 diabetes in Asia (the JADE programme): a cross-sectional study of a prospective cohort</article-title>. <source>Lancet Diabetes Endocrinol</source>. (<year>2014</year>) <volume>2</volume>:<page-range>935&#x2013;43</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1016/S2213-8587(14)70137-8</pub-id>
</citation>
</ref>
<ref id="B28">
<label>28</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Zeitler</surname> <given-names>P</given-names>
</name>
<name>
<surname>Epstein</surname> <given-names>L</given-names>
</name>
<name>
<surname>Grey</surname> <given-names>M</given-names>
</name>
<name>
<surname>Hirst</surname> <given-names>K</given-names>
</name>
<name>
<surname>Kaufman</surname> <given-names>F</given-names>
</name>
<name>
<surname>Tamborlane</surname> <given-names>W</given-names>
</name>
<etal/>
</person-group>. <article-title>Treatment options for type 2 diabetes in adolescents and youth: a study of the comparative efficacy of metformin alone or in combination with rosiglitazone or lifestyle intervention in adolescents with type 2 diabetes</article-title>. <source>Pediatr Diabetes</source>. (<year>2007</year>) <volume>8</volume>:<fpage>74</fpage>&#x2013;<lpage>87</lpage>. doi:&#xa0;<pub-id pub-id-type="doi">10.1111/j.1399-5448.2007.00237.x</pub-id>
</citation>
</ref>
<ref id="B29">
<label>29</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Sanderson</surname> <given-names>EE</given-names>
</name>
<name>
<surname>Shah</surname> <given-names>M</given-names>
</name>
<name>
<surname>Hooper</surname> <given-names>AJ</given-names>
</name>
<name>
<surname>Bell</surname> <given-names>DA</given-names>
</name>
<name>
<surname>Choong</surname> <given-names>CS</given-names>
</name>
</person-group>. <article-title>Monogenic diabetes due to an INSR mutation in a child with severe insulin resistance</article-title>. <source>Endocrinol Diabetes Metab Case Rep</source>. (<year>2022</year>) <volume>2022</volume>:<page-range>21-0114</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1530/EDM-21-0114</pub-id>
</citation>
</ref>
<ref id="B30">
<label>30</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ali</surname> <given-names>O</given-names>
</name>
</person-group>. <article-title>Genetics of type 2 diabetes</article-title>. <source>World J Diabetes</source>. (<year>2013</year>) <volume>4</volume>:<page-range>114&#x2013;23</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.4239/wjd.v4.i4.114</pub-id>
</citation>
</ref>
<ref id="B31">
<label>31</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Franks</surname> <given-names>PW</given-names>
</name>
<name>
<surname>Looker</surname> <given-names>HC</given-names>
</name>
<name>
<surname>Kobes</surname> <given-names>S</given-names>
</name>
<name>
<surname>Touger</surname> <given-names>L</given-names>
</name>
<name>
<surname>Tataranni</surname> <given-names>PA</given-names>
</name>
<name>
<surname>Hanson</surname> <given-names>RL</given-names>
</name>
<etal/>
</person-group>. <article-title>Gestational glucose tolerance and risk of type 2 diabetes in young Pima Indian offspring</article-title>. <source>Diabetes</source>. (<year>2006</year>) <volume>55</volume>:<page-range>460&#x2013;5</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.2337/diabetes.55.02.06.db05-0823</pub-id>
</citation>
</ref>
<ref id="B32">
<label>32</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Shah</surname> <given-names>RD</given-names>
</name>
<name>
<surname>Chernausek</surname> <given-names>SD</given-names>
</name>
<name>
<surname>El Ghormli</surname> <given-names>L</given-names>
</name>
<name>
<surname>Geffner</surname> <given-names>ME</given-names>
</name>
<name>
<surname>Keady</surname> <given-names>J</given-names>
</name>
<name>
<surname>Kelsey</surname> <given-names>MM</given-names>
</name>
<etal/>
</person-group>. <article-title>Maternal diabetes in youth-onset type 2 diabetes is associated with progressive dysglycemia and risk of complications</article-title>. <source>J Clin Endocrinol Metab</source>. (<year>2023</year>) <volume>108</volume>:<page-range>1120&#x2013;31</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1210/clinem/dgac663</pub-id>
</citation>
</ref>
<ref id="B33">
<label>33</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Yang</surname> <given-names>L</given-names>
</name>
<name>
<surname>Huang</surname> <given-names>C</given-names>
</name>
<name>
<surname>Zhao</surname> <given-names>M</given-names>
</name>
<name>
<surname>Lee</surname> <given-names>PMY</given-names>
</name>
<name>
<surname>Zhang</surname> <given-names>C</given-names>
</name>
<name>
<surname>Yu</surname> <given-names>Y</given-names>
</name>
<etal/>
</person-group>. <article-title>Maternal hypertensive disorders during pregnancy and the risk of offspring diabetes mellitus in childhood, adolescence, and early adulthood: a nationwide population-based cohort study</article-title>. <source>BMC Med</source>. (<year>2023</year>) <volume>21</volume>:<fpage>59</fpage>. doi:&#xa0;<pub-id pub-id-type="doi">10.1186/s12916-023-02762-5</pub-id>
</citation>
</ref>
<ref id="B34">
<label>34</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Blasetti</surname> <given-names>A</given-names>
</name>
<name>
<surname>Quarta</surname> <given-names>A</given-names>
</name>
<name>
<surname>Guarino</surname> <given-names>M</given-names>
</name>
<name>
<surname>Cicolini</surname> <given-names>I</given-names>
</name>
<name>
<surname>Iannucci</surname> <given-names>D</given-names>
</name>
<name>
<surname>Giannini</surname> <given-names>C</given-names>
</name>
<etal/>
</person-group>. <article-title>Role of prenatal nutrition in the development of insulin resistance in children</article-title>. <source>Nutrients</source>. (<year>2022</year>) <volume>15</volume>:<page-range>87</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.3390/nu15010087</pub-id>
</citation>
</ref>
<ref id="B35">
<label>35</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Srinivasan</surname> <given-names>S</given-names>
</name>
<name>
<surname>Chen</surname> <given-names>L</given-names>
</name>
<name>
<surname>Todd</surname> <given-names>J</given-names>
</name>
<name>
<surname>Divers</surname> <given-names>J</given-names>
</name>
<name>
<surname>Gidding</surname> <given-names>S</given-names>
</name>
<name>
<surname>Chernausek</surname> <given-names>S</given-names>
</name>
<etal/>
</person-group>. <article-title>The first genome-wide association study for type 2 diabetes in youth: the progress in diabetes genetics in youth (ProDiGY) consortium</article-title>. <source>Diabetes</source>. (<year>2021</year>) <volume>70</volume>:<fpage>996</fpage>&#x2013;<lpage>1005</lpage>. doi:&#xa0;<pub-id pub-id-type="doi">10.2337/db20-0443</pub-id>
</citation>
</ref>
<ref id="B36">
<label>36</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Gao</surname> <given-names>J</given-names>
</name>
<name>
<surname>Lu</surname> <given-names>Y</given-names>
</name>
<name>
<surname>Gokulnath</surname> <given-names>P</given-names>
</name>
<name>
<surname>Vulugundam</surname> <given-names>G</given-names>
</name>
<name>
<surname>Li</surname> <given-names>G</given-names>
</name>
<name>
<surname>Li</surname> <given-names>J</given-names>
</name>
<etal/>
</person-group>. <article-title>Benefits of physical activity on cardiometabolic diseases in obese children and adolescents</article-title>. <source>J Transl Int Med</source>. (<year>2022</year>) <volume>10</volume>:<page-range>236&#x2013;45</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.2478/jtim-2022-0041</pub-id>
</citation>
</ref>
<ref id="B37">
<label>37</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Abbasi</surname> <given-names>A</given-names>
</name>
<name>
<surname>Juszczyk</surname> <given-names>D</given-names>
</name>
<name>
<surname>van Jaarsveld</surname> <given-names>CHM</given-names>
</name>
<name>
<surname>Gulliford</surname> <given-names>MC</given-names>
</name>
</person-group>. <article-title>Body mass index and incident type 1 and type 2 diabetes in children and young adults: A retrospective cohort study</article-title>. <source>J Endocr Soc</source>. (<year>2017</year>) <volume>1</volume>:<page-range>524&#x2013;37</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1210/js.2017-00044</pub-id>
</citation>
</ref>
<ref id="B38">
<label>38</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Stanhope</surname> <given-names>KL</given-names>
</name>
</person-group>. <article-title>Sugar consumption, metabolic disease and obesity: The state of the controversy</article-title>. <source>Crit Rev Clin Lab Sci</source>. (<year>2016</year>) <volume>53</volume>:<fpage>52</fpage>&#x2013;<lpage>67</lpage>. doi:&#xa0;<pub-id pub-id-type="doi">10.3109/10408363.2015.1084990</pub-id>
</citation>
</ref>
<ref id="B39">
<label>39</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Barnard</surname> <given-names>N</given-names>
</name>
<name>
<surname>Levin</surname> <given-names>S</given-names>
</name>
<name>
<surname>Trapp</surname> <given-names>C</given-names>
</name>
</person-group>. <article-title>Meat consumption as a risk factor for type 2 diabetes</article-title>. <source>Nutrients</source>. (<year>2014</year>) <volume>6</volume>:<fpage>897</fpage>&#x2013;<lpage>910</lpage>. doi:&#xa0;<pub-id pub-id-type="doi">10.3390/nu6020897</pub-id>
</citation>
</ref>
<ref id="B40">
<label>40</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Bleich</surname> <given-names>SN</given-names>
</name>
<name>
<surname>Vercammen</surname> <given-names>KA</given-names>
</name>
</person-group>. <article-title>The negative impact of sugar-sweetened beverages on children&#x2019;s health: an update of the literature</article-title>. <source>BMC Obes</source>. (<year>2018</year>) <volume>5</volume>:<fpage>6</fpage>. doi:&#xa0;<pub-id pub-id-type="doi">10.1186/s40608-017-0178-9</pub-id>
</citation>
</ref>
<ref id="B41">
<label>41</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Bray</surname> <given-names>GA</given-names>
</name>
<name>
<surname>Popkin</surname> <given-names>BM</given-names>
</name>
</person-group>. <article-title>Dietary fat intake does affect obesity</article-title>! <source>Am J Clin Nutr</source>. (<year>1998</year>) <volume>68</volume>:<page-range>1157&#x2013;73</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1093/ajcn/68.6.1157</pub-id>
</citation>
</ref>
<ref id="B42">
<label>42</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Duffey</surname> <given-names>KJ</given-names>
</name>
<name>
<surname>Gordon-Larsen</surname> <given-names>P</given-names>
</name>
<name>
<surname>Steffen</surname> <given-names>LM</given-names>
</name>
<name>
<surname>Jacobs</surname> <given-names>DR</given-names>
<suffix>Jr.</suffix>
</name>
<name>
<surname>Popkin</surname> <given-names>BM</given-names>
</name>
</person-group>. <article-title>Regular consumption from fast food establishments relative to other restaurants is differentially associated with metabolic outcomes in young adults</article-title>. <source>J Nutr</source>. (<year>2009</year>) <volume>139</volume>:<page-range>2113&#x2013;8</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.3945/jn.109.109520</pub-id>
</citation>
</ref>
<ref id="B43">
<label>43</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Lawrence</surname> <given-names>JM</given-names>
</name>
<name>
<surname>Divers</surname> <given-names>J</given-names>
</name>
<name>
<surname>Isom</surname> <given-names>S</given-names>
</name>
<name>
<surname>Saydah</surname> <given-names>S</given-names>
</name>
<name>
<surname>Imperatore</surname> <given-names>G</given-names>
</name>
<name>
<surname>Pihoker</surname> <given-names>C</given-names>
</name>
<etal/>
</person-group>. <article-title>Trends in prevalence of type 1 and type 2 diabetes in children and adolescents in the US, 2001&#x2013;2017</article-title>. <source>Jama</source>. (<year>2021</year>) <volume>326</volume>:<page-range>717&#x2013;27</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1001/jama.2021.11165</pub-id>
</citation>
</ref>
<ref id="B44">
<label>44</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Skinner</surname> <given-names>AC</given-names>
</name>
<name>
<surname>Ravanbakht</surname> <given-names>SN</given-names>
</name>
<name>
<surname>Skelton</surname> <given-names>JA</given-names>
</name>
<name>
<surname>Perrin</surname> <given-names>EM</given-names>
</name>
<name>
<surname>Armstrong</surname> <given-names>SC</given-names>
</name>
</person-group>. <article-title>Prevalence of obesity and severe obesity in US children, 1999&#x2013;2016</article-title>. <source>Pediatrics</source>. (<year>2018</year>) <volume>141</volume>:<page-range>e20181916</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1542/peds.2017-3459</pub-id>
</citation>
</ref>
<ref id="B45">
<label>45</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Karin</surname> <given-names>A</given-names>
</name>
<name>
<surname>Jon</surname> <given-names>E</given-names>
</name>
<name>
<surname>Martin</surname> <given-names>A</given-names>
</name>
<name>
<surname>Lena</surname> <given-names>B</given-names>
</name>
<name>
<surname>Martin</surname> <given-names>L</given-names>
</name>
<name>
<surname>Naveed</surname> <given-names>S</given-names>
</name>
<etal/>
</person-group>. <article-title>Body mass index in adolescence, risk of type 2 diabetes and associated complications: A nationwide cohort study of men</article-title>. <source>EClinicalMedicine</source>. (<year>2022</year>) <volume>46</volume>:<fpage>101356</fpage>. doi:&#xa0;<pub-id pub-id-type="doi">10.1016/j.eclinm.2022.101356</pub-id>
</citation>
</ref>
<ref id="B46">
<label>46</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>He</surname> <given-names>QX</given-names>
</name>
<name>
<surname>Zhao</surname> <given-names>L</given-names>
</name>
<name>
<surname>Tong</surname> <given-names>JS</given-names>
</name>
<name>
<surname>Liang</surname> <given-names>XY</given-names>
</name>
<name>
<surname>Li</surname> <given-names>RN</given-names>
</name>
<name>
<surname>Zhang</surname> <given-names>P</given-names>
</name>
<etal/>
</person-group>. <article-title>The impact of obesity epidemic on type 2 diabetes in children and adolescents: A systematic review and meta-analysis</article-title>. <source>Prim Care Diabetes</source>. (<year>2022</year>) <volume>16</volume>:<page-range>736&#x2013;44</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1016/j.pcd.2022.09.006</pub-id>
</citation>
</ref>
<ref id="B47">
<label>47</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Twig</surname> <given-names>G</given-names>
</name>
<name>
<surname>Zucker</surname> <given-names>I</given-names>
</name>
<name>
<surname>Afek</surname> <given-names>A</given-names>
</name>
<name>
<surname>Cukierman-Yaffe</surname> <given-names>T</given-names>
</name>
<name>
<surname>Bendor</surname> <given-names>CD</given-names>
</name>
<name>
<surname>Derazne</surname> <given-names>E</given-names>
</name>
<etal/>
</person-group>. <article-title>Adolescent obesity and early-onset type 2 diabetes</article-title>. <source>Diabetes Care</source>. (<year>2020</year>) <volume>43</volume>:<page-range>1487&#x2013;95</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.2337/dc19-1988</pub-id>
</citation>
</ref>
<ref id="B48">
<label>48</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Hood</surname> <given-names>KK</given-names>
</name>
<name>
<surname>Beavers</surname> <given-names>DP</given-names>
</name>
<name>
<surname>Yi-Frazier</surname> <given-names>J</given-names>
</name>
<name>
<surname>Bell</surname> <given-names>R</given-names>
</name>
<name>
<surname>Dabelea</surname> <given-names>D</given-names>
</name>
<name>
<surname>McKeown</surname> <given-names>RE</given-names>
</name>
<etal/>
</person-group>. <article-title>Psychosocial burden and glycemic control during the first 6 years of diabetes: results from the SEARCH for Diabetes in Youth study</article-title>. <source>J Adolesc Health</source>. (<year>2014</year>) <volume>55</volume>:<fpage>498</fpage>&#x2013;<lpage>504</lpage>. doi:&#xa0;<pub-id pub-id-type="doi">10.1016/j.jadohealth.2014.03.011</pub-id>
</citation>
</ref>
<ref id="B49">
<label>49</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Hsu</surname> <given-names>JW</given-names>
</name>
<name>
<surname>Chen</surname> <given-names>LC</given-names>
</name>
<name>
<surname>Huang</surname> <given-names>KL</given-names>
</name>
<name>
<surname>Tsai</surname> <given-names>SJ</given-names>
</name>
<name>
<surname>Bai</surname> <given-names>YM</given-names>
</name>
<name>
<surname>Su</surname> <given-names>TP</given-names>
</name>
<etal/>
</person-group>. <article-title>Risk of type 2 diabetes mellitus between adolescents with antidepressant-resistant and antidepressant-responsive depression: A cohort study of 15,651 adolescents</article-title>. <source>J Affect Disord</source>. (<year>2023</year>) <volume>328</volume>:<page-range>210&#x2013;4</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1016/j.jad.2023.02.065</pub-id>
</citation>
</ref>
<ref id="B50">
<label>50</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Snyder</surname> <given-names>LL</given-names>
</name>
<name>
<surname>Foland-Ross</surname> <given-names>LC</given-names>
</name>
<name>
<surname>Cato</surname> <given-names>A</given-names>
</name>
<name>
<surname>Reiss</surname> <given-names>AL</given-names>
</name>
<name>
<surname>Shah</surname> <given-names>C</given-names>
</name>
<name>
<surname>Hossain</surname> <given-names>J</given-names>
</name>
<etal/>
</person-group>. <article-title>Impact of dysglycemia and obesity on the brain in adolescents with and without type 2 diabetes: A pilot study</article-title>. <source>Pediatr Diabetes</source>. (<year>2022</year>) <volume>23</volume>:<page-range>1674&#x2013;86</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1111/pedi.13420</pub-id>
</citation>
</ref>
<ref id="B51">
<label>51</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Galicia-Garcia</surname> <given-names>U</given-names>
</name>
<name>
<surname>Benito-Vicente</surname> <given-names>A</given-names>
</name>
<name>
<surname>Jebari</surname> <given-names>S</given-names>
</name>
<name>
<surname>Larrea-Sebal</surname> <given-names>A</given-names>
</name>
<name>
<surname>Siddiqi</surname> <given-names>H</given-names>
</name>
<name>
<surname>Uribe</surname> <given-names>KB</given-names>
</name>
<etal/>
</person-group>. <article-title>Pathophysiology of type 2 diabetes mellitus</article-title>. <source>Int J Mol Sci</source>. (<year>2020</year>) <volume>21</volume>:<page-range>6275</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.3390/ijms21176275</pub-id>
</citation>
</ref>
<ref id="B52">
<label>52</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Zhao</surname> <given-names>X</given-names>
</name>
<name>
<surname>An</surname> <given-names>X</given-names>
</name>
<name>
<surname>Yang</surname> <given-names>C</given-names>
</name>
<name>
<surname>Sun</surname> <given-names>W</given-names>
</name>
<name>
<surname>Ji</surname> <given-names>H</given-names>
</name>
<name>
<surname>Lian</surname> <given-names>F</given-names>
</name>
</person-group>. <article-title>The crucial role and mechanism of insulin resistance in metabolic disease</article-title>. <source>Front Endocrinol (Lausanne)</source>. (<year>2023</year>) <volume>14</volume>:<elocation-id>1149239</elocation-id>. doi:&#xa0;<pub-id pub-id-type="doi">10.3389/fendo.2023.1149239</pub-id>
</citation>
</ref>
<ref id="B53">
<label>53</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>James</surname> <given-names>DE</given-names>
</name>
<name>
<surname>St&#xf6;ckli</surname> <given-names>J</given-names>
</name>
<name>
<surname>Birnbaum</surname> <given-names>MJ</given-names>
</name>
</person-group>. <article-title>The aetiology and molecular landscape of insulin resistance</article-title>. <source>Nat Rev Mol Cell Biol</source>. (<year>2021</year>) <volume>22</volume>:<page-range>751&#x2013;71</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1038/s41580-021-00390-6</pub-id>
</citation>
</ref>
<ref id="B54">
<label>54</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Assun&#xe7;&#xe3;o</surname> <given-names>SNF</given-names>
</name>
<name>
<surname>Boa Sorte</surname> <given-names>NCA</given-names>
</name>
<name>
<surname>Alves</surname> <given-names>CAD</given-names>
</name>
<name>
<surname>Mendes</surname> <given-names>PSA</given-names>
</name>
<name>
<surname>Alves</surname> <given-names>CRB</given-names>
</name>
<name>
<surname>Silva</surname> <given-names>LR</given-names>
</name>
</person-group>. <article-title>Glucose alteration and insulin resistance in asymptomatic obese children and adolescents</article-title>. <source>J Pediatr (Rio J)</source>. (<year>2018</year>) <volume>94</volume>:<page-range>268&#x2013;72</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1016/j.jped.2017.06.008</pub-id>
</citation>
</ref>
<ref id="B55">
<label>55</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Xourafa</surname> <given-names>G</given-names>
</name>
<name>
<surname>Korbmacher</surname> <given-names>M</given-names>
</name>
<name>
<surname>Roden</surname> <given-names>M</given-names>
</name>
</person-group>. <article-title>Inter-organ crosstalk during development and progression of type 2 diabetes mellitus</article-title>. <source>Nat Rev Endocrinol</source>. (<year>2024</year>) <volume>20</volume>:<fpage>27</fpage>&#x2013;<lpage>49</lpage>. doi:&#xa0;<pub-id pub-id-type="doi">10.1038/s41574-023-00898-1</pub-id>
</citation>
</ref>
<ref id="B56">
<label>56</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Nguyen</surname> <given-names>MT</given-names>
</name>
<name>
<surname>Satoh</surname> <given-names>H</given-names>
</name>
<name>
<surname>Favelyukis</surname> <given-names>S</given-names>
</name>
<name>
<surname>Babendure</surname> <given-names>JL</given-names>
</name>
<name>
<surname>Imamura</surname> <given-names>T</given-names>
</name>
<name>
<surname>Sbodio</surname> <given-names>JI</given-names>
</name>
<etal/>
</person-group>. <article-title>JNK and tumor necrosis factor-alpha mediate free fatty acid-induced insulin resistance in 3T3-L1 adipocytes</article-title>. <source>J Biol Chem</source>. (<year>2005</year>) <volume>280</volume>:<page-range>35361&#x2013;71</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1074/jbc.M504611200</pub-id>
</citation>
</ref>
<ref id="B57">
<label>57</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Lin</surname> <given-names>SC</given-names>
</name>
<name>
<surname>Hardie</surname> <given-names>DG</given-names>
</name>
</person-group>. <article-title>AMPK: sensing glucose as well as cellular energy status</article-title>. <source>Cell Metab</source>. (<year>2018</year>) <volume>27</volume>:<fpage>299</fpage>&#x2013;<lpage>313</lpage>. doi:&#xa0;<pub-id pub-id-type="doi">10.1016/j.cmet.2017.10.009</pub-id>
</citation>
</ref>
<ref id="B58">
<label>58</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Venable</surname> <given-names>CL</given-names>
</name>
<name>
<surname>Frevert</surname> <given-names>EU</given-names>
</name>
<name>
<surname>Kim</surname> <given-names>YB</given-names>
</name>
<name>
<surname>Fischer</surname> <given-names>BM</given-names>
</name>
<name>
<surname>Kamatkar</surname> <given-names>S</given-names>
</name>
<name>
<surname>Neel</surname> <given-names>BG</given-names>
</name>
<etal/>
</person-group>. <article-title>Overexpression of protein-tyrosine phosphatase-1B in adipocytes inhibits insulin-stimulated phosphoinositide 3-kinase activity without altering glucose transport or Akt/Protein kinase B activation</article-title>. <source>J Biol Chem</source>. (<year>2000</year>) <volume>275</volume>:<page-range>18318&#x2013;26</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1074/jbc.M908392199</pub-id>
</citation>
</ref>
<ref id="B59">
<label>59</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Leto</surname> <given-names>D</given-names>
</name>
<name>
<surname>Saltiel</surname> <given-names>AR</given-names>
</name>
</person-group>. <article-title>Regulation of glucose transport by insulin: traffic control of GLUT4</article-title>. <source>Nat Rev Mol Cell Biol</source>. (<year>2012</year>) <volume>13</volume>:<page-range>383&#x2013;96</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1038/nrm3351</pub-id>
</citation>
</ref>
<ref id="B60">
<label>60</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ahmed</surname> <given-names>B</given-names>
</name>
<name>
<surname>Sultana</surname> <given-names>R</given-names>
</name>
<name>
<surname>Greene</surname> <given-names>MW</given-names>
</name>
</person-group>. <article-title>Adipose tissue and insulin resistance in obese</article-title>. <source>BioMed Pharmacother</source>. (<year>2021</year>) <volume>137</volume>:<fpage>111315</fpage>. doi:&#xa0;<pub-id pub-id-type="doi">10.1016/j.biopha.2021.111315</pub-id>
</citation>
</ref>
<ref id="B61">
<label>61</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Li</surname> <given-names>C</given-names>
</name>
<name>
<surname>Xu</surname> <given-names>MM</given-names>
</name>
<name>
<surname>Wang</surname> <given-names>K</given-names>
</name>
<name>
<surname>Adler</surname> <given-names>AJ</given-names>
</name>
<name>
<surname>Vella</surname> <given-names>AT</given-names>
</name>
<name>
<surname>Zhou</surname> <given-names>B</given-names>
</name>
</person-group>. <article-title>Macrophage polarization and meta-inflammation</article-title>. <source>Transl Res</source>. (<year>2018</year>) <volume>191</volume>:<fpage>29</fpage>&#x2013;<lpage>44</lpage>. doi:&#xa0;<pub-id pub-id-type="doi">10.1016/j.trsl.2017.10.004</pub-id>
</citation>
</ref>
<ref id="B62">
<label>62</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Chen</surname> <given-names>G</given-names>
</name>
<name>
<surname>Ni</surname> <given-names>Y</given-names>
</name>
<name>
<surname>Nagata</surname> <given-names>N</given-names>
</name>
<name>
<surname>Xu</surname> <given-names>L</given-names>
</name>
<name>
<surname>Zhuge</surname> <given-names>F</given-names>
</name>
<name>
<surname>Nagashimada</surname> <given-names>M</given-names>
</name>
<etal/>
</person-group>. <article-title>Pirfenidone prevents and reverses hepatic insulin resistance and steatohepatitis by polarizing M2 macrophages</article-title>. <source>Lab Invest</source>. (<year>2019</year>) <volume>99</volume>:<page-range>1335&#x2013;48</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1038/s41374-019-0255-4</pub-id>
</citation>
</ref>
<ref id="B63">
<label>63</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Glass</surname> <given-names>CK</given-names>
</name>
<name>
<surname>Olefsky</surname> <given-names>JM</given-names>
</name>
</person-group>. <article-title>Inflammation and lipid signaling in the etiology of insulin resistance</article-title>. <source>Cell Metab</source>. (<year>2012</year>) <volume>15</volume>:<page-range>635&#x2013;45</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1016/j.cmet.2012.04.001</pub-id>
</citation>
</ref>
<ref id="B64">
<label>64</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Shoelson</surname> <given-names>SE</given-names>
</name>
<name>
<surname>Lee</surname> <given-names>J</given-names>
</name>
<name>
<surname>Goldfine</surname> <given-names>AB</given-names>
</name>
</person-group>. <article-title>Inflammation and insulin resistance</article-title>. <source>J Clin Invest</source>. (<year>2006</year>) <volume>116</volume>:<page-range>1793&#x2013;801</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1172/JCI29069</pub-id>
</citation>
</ref>
<ref id="B65">
<label>65</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Qatanani</surname> <given-names>M</given-names>
</name>
<name>
<surname>Lazar</surname> <given-names>MA</given-names>
</name>
</person-group>. <article-title>Mechanisms of obesity-associated insulin resistance: many choices on the menu</article-title>. <source>Genes Dev</source>. (<year>2007</year>) <volume>21</volume>:<page-range>1443&#x2013;55</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1101/gad.1550907</pub-id>
</citation>
</ref>
<ref id="B66">
<label>66</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kwak</surname> <given-names>HJ</given-names>
</name>
<name>
<surname>Yang</surname> <given-names>D</given-names>
</name>
<name>
<surname>Hwang</surname> <given-names>Y</given-names>
</name>
<name>
<surname>Jun</surname> <given-names>HS</given-names>
</name>
<name>
<surname>Cheon</surname> <given-names>HG</given-names>
</name>
</person-group>. <article-title>Baicalein protects rat insulinoma INS-1 cells from palmitate-induced lipotoxicity by inducing HO-1</article-title>. <source>PloS One</source>. (<year>2017</year>) <volume>12</volume>:<elocation-id>e0176432</elocation-id>. doi:&#xa0;<pub-id pub-id-type="doi">10.1371/journal.pone.0176432</pub-id>
</citation>
</ref>
<ref id="B67">
<label>67</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Evans</surname> <given-names>JL</given-names>
</name>
<name>
<surname>Maddux</surname> <given-names>BA</given-names>
</name>
<name>
<surname>Goldfine</surname> <given-names>ID</given-names>
</name>
</person-group>. <article-title>The molecular basis for oxidative stress-induced insulin resistance</article-title>. <source>Antioxid Redox Signal</source>. (<year>2005</year>) <volume>7</volume>:<page-range>1040&#x2013;52</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1089/ars.2005.7.1040</pub-id>
</citation>
</ref>
<ref id="B68">
<label>68</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Hurrle</surname> <given-names>S</given-names>
</name>
<name>
<surname>Hsu</surname> <given-names>WH</given-names>
</name>
</person-group>. <article-title>The etiology of oxidative stress in insulin resistance</article-title>. <source>BioMed J</source>. (<year>2017</year>) <volume>40</volume>:<page-range>257&#x2013;62</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1016/j.bj.2017.06.007</pub-id>
</citation>
</ref>
<ref id="B69">
<label>69</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Gungor</surname> <given-names>N</given-names>
</name>
<name>
<surname>Bacha</surname> <given-names>F</given-names>
</name>
<name>
<surname>Saad</surname> <given-names>R</given-names>
</name>
<name>
<surname>Janosky</surname> <given-names>J</given-names>
</name>
<name>
<surname>Arslanian</surname> <given-names>S</given-names>
</name>
</person-group>. <article-title>Youth type 2 diabetes: insulin resistance, beta-cell failure, or both</article-title>? <source>Diabetes Care</source>. (<year>2005</year>) <volume>28</volume>:<page-range>638&#x2013;44</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.2337/diacare.28.3.638</pub-id>
</citation>
</ref>
<ref id="B70">
<label>70</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Mbanya</surname> <given-names>JC</given-names>
</name>
<name>
<surname>Motala</surname> <given-names>AA</given-names>
</name>
<name>
<surname>Sobngwi</surname> <given-names>E</given-names>
</name>
<name>
<surname>Assah</surname> <given-names>FK</given-names>
</name>
<name>
<surname>Enoru</surname> <given-names>ST</given-names>
</name>
</person-group>. <article-title>Diabetes in sub-saharan africa</article-title>. <source>Lancet</source>. (<year>2010</year>) <volume>375</volume>:<page-range>2254&#x2013;66</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1016/S0140-6736(10)60550-8</pub-id>
</citation>
</ref>
<ref id="B71">
<label>71</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Yajnik</surname> <given-names>CS</given-names>
</name>
</person-group>. <article-title>The lifecycle effects of nutrition and body size on adult adiposity, diabetes and cardiovascular disease</article-title>. <source>Obes Rev</source>. (<year>2002</year>) <volume>3</volume>:<page-range>217&#x2013;24</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1046/j.1467-789X.2002.00072.x</pub-id>
</citation>
</ref>
<ref id="B72">
<label>72</label>
<citation citation-type="journal">
<collab>RISE Consortium</collab>. <article-title>Metabolic contrasts between youth and adults with impaired glucose tolerance or recently diagnosed type 2 diabetes: II. Observations using the oral glucose tolerance test</article-title>. <source>Diabetes Care</source>. (<year>2018</year>) <volume>41</volume>:<page-range>1707&#x2013;16</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.2337/dc18-0243</pub-id>
</citation>
</ref>
<ref id="B73">
<label>73</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Cohrs</surname> <given-names>CM</given-names>
</name>
<name>
<surname>Panzer</surname> <given-names>JK</given-names>
</name>
<name>
<surname>Drotar</surname> <given-names>DM</given-names>
</name>
<name>
<surname>Enos</surname> <given-names>SJ</given-names>
</name>
<name>
<surname>Kipke</surname> <given-names>N</given-names>
</name>
<name>
<surname>Chen</surname> <given-names>C</given-names>
</name>
<etal/>
</person-group>. <article-title>Dysfunction of persisting &#x3b2; Cells is a key feature of early type 2 diabetes pathogenesis</article-title>. <source>Cell Rep</source>. (<year>2020</year>) <volume>31</volume>:<fpage>107469</fpage>. doi:&#xa0;<pub-id pub-id-type="doi">10.1016/j.celrep.2020.03.033</pub-id>
</citation>
</ref>
<ref id="B74">
<label>74</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Gobato</surname> <given-names>AO</given-names>
</name>
<name>
<surname>Vasques</surname> <given-names>AC</given-names>
</name>
<name>
<surname>Zambon</surname> <given-names>MP</given-names>
</name>
<name>
<surname>Barros Filho Ade</surname> <given-names>A</given-names>
</name>
<name>
<surname>Hessel</surname> <given-names>G</given-names>
</name>
</person-group>. <article-title>Metabolic syndrome and insulin resistance in obese adolescents</article-title>. <source>Rev Paul Pediatr</source>. (<year>2014</year>) <volume>32</volume>:<fpage>55</fpage>&#x2013;<lpage>62</lpage>. doi:&#xa0;<pub-id pub-id-type="doi">10.1590/S0103-05822014000100010</pub-id>
</citation>
</ref>
<ref id="B75">
<label>75</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Huang</surname> <given-names>RC</given-names>
</name>
<name>
<surname>de Klerk</surname> <given-names>NH</given-names>
</name>
<name>
<surname>Smith</surname> <given-names>A</given-names>
</name>
<name>
<surname>Kendall</surname> <given-names>GE</given-names>
</name>
<name>
<surname>Landau</surname> <given-names>LI</given-names>
</name>
<name>
<surname>Mori</surname> <given-names>TA</given-names>
</name>
<etal/>
</person-group>. <article-title>Lifecourse childhood adiposity trajectories associated with adolescent insulin resistance</article-title>. <source>Diabetes Care</source>. (<year>2011</year>) <volume>34</volume>:<page-range>1019&#x2013;25</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.2337/dc10-1809</pub-id>
</citation>
</ref>
<ref id="B76">
<label>76</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Peplies</surname> <given-names>J</given-names>
</name>
<name>
<surname>B&#xf6;rnhorst</surname> <given-names>C</given-names>
</name>
<name>
<surname>G&#xfc;nther</surname> <given-names>K</given-names>
</name>
<name>
<surname>Fraterman</surname> <given-names>A</given-names>
</name>
<name>
<surname>Russo</surname> <given-names>P</given-names>
</name>
<name>
<surname>Veidebaum</surname> <given-names>T</given-names>
</name>
<etal/>
</person-group>. <article-title>Longitudinal associations of lifestyle factors and weight status with insulin resistance (HOMA-IR) in preadolescent children: the large prospective cohort study IDEFICS</article-title>. <source>Int J Behav Nutr Phys Act</source>. (<year>2016</year>) <volume>13</volume>:<fpage>97</fpage>. doi:&#xa0;<pub-id pub-id-type="doi">10.1186/s12966-016-0424-4</pub-id>
</citation>
</ref>
<ref id="B77">
<label>77</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kobayashi</surname> <given-names>K</given-names>
</name>
<name>
<surname>Amemiya</surname> <given-names>S</given-names>
</name>
<name>
<surname>Higashida</surname> <given-names>K</given-names>
</name>
<name>
<surname>Ishihara</surname> <given-names>T</given-names>
</name>
<name>
<surname>Sawanobori</surname> <given-names>E</given-names>
</name>
<name>
<surname>Kobayashi</surname> <given-names>K</given-names>
</name>
<etal/>
</person-group>. <article-title>Pathogenic factors of glucose intolerance in obese Japanese adolescents with type 2 diabetes</article-title>. <source>Metabolism</source>. (<year>2000</year>) <volume>49</volume>:<page-range>186&#x2013;91</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1016/S0026-0495(00)91221-6</pub-id>
</citation>
</ref>
<ref id="B78">
<label>78</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>van der Aa</surname> <given-names>MP</given-names>
</name>
<name>
<surname>Fazeli Farsani</surname> <given-names>S</given-names>
</name>
<name>
<surname>Knibbe</surname> <given-names>CA</given-names>
</name>
<name>
<surname>de Boer</surname> <given-names>A</given-names>
</name>
<name>
<surname>van der Vorst</surname> <given-names>MM</given-names>
</name>
</person-group>. <article-title>Population-based studies on the epidemiology of insulin resistance in children</article-title>. <source>J Diabetes Res</source>. (<year>2015</year>) <volume>2015</volume>:<fpage>362375</fpage>. doi:&#xa0;<pub-id pub-id-type="doi">10.1155/2015/362375</pub-id>
</citation>
</ref>
<ref id="B79">
<label>79</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Temneanu</surname> <given-names>OR</given-names>
</name>
<name>
<surname>Trandafir</surname> <given-names>LM</given-names>
</name>
<name>
<surname>Purcarea</surname> <given-names>MR</given-names>
</name>
</person-group>. <article-title>Type 2 diabetes mellitus in children and adolescents: a relatively new clinical problem within pediatric practice</article-title>. <source>J Med Life</source>. (<year>2016</year>) <volume>9</volume>:<page-range>235&#x2013;9</page-range>.</citation>
</ref>
<ref id="B80">
<label>80</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Androutsos</surname> <given-names>O</given-names>
</name>
<name>
<surname>Moschonis</surname> <given-names>G</given-names>
</name>
<name>
<surname>Mavrogianni</surname> <given-names>C</given-names>
</name>
<name>
<surname>Roma-Giannikou</surname> <given-names>E</given-names>
</name>
<name>
<surname>Chrousos</surname> <given-names>GP</given-names>
</name>
<name>
<surname>Kanaka-Gantenbein</surname> <given-names>C</given-names>
</name>
<etal/>
</person-group>. <article-title>Identification of lifestyle patterns, including sleep deprivation, associated with insulin resistance in children: the Healthy Growth Study</article-title>. <source>Eur J Clin Nutr</source>. (<year>2014</year>) <volume>68</volume>:<page-range>344&#x2013;9</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1038/ejcn.2013.280</pub-id>
</citation>
</ref>
<ref id="B81">
<label>81</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Nip</surname> <given-names>ASY</given-names>
</name>
<name>
<surname>Reboussin</surname> <given-names>BA</given-names>
</name>
<name>
<surname>Dabelea</surname> <given-names>D</given-names>
</name>
<name>
<surname>Bellatorre</surname> <given-names>A</given-names>
</name>
<name>
<surname>Mayer-Davis</surname> <given-names>EJ</given-names>
</name>
<name>
<surname>Kahkoska</surname> <given-names>AR</given-names>
</name>
<etal/>
</person-group>. <article-title>Disordered eating behaviors in youth and young adults with type 1 or type 2 diabetes receiving insulin therapy: the SEARCH for diabetes in youth study</article-title>. <source>Diabetes Care</source>. (<year>2019</year>) <volume>42</volume>:<page-range>859&#x2013;66</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.2337/dc18-2420</pub-id>
</citation>
</ref>
<ref id="B82">
<label>82</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Corica</surname> <given-names>D</given-names>
</name>
<name>
<surname>Pepe</surname> <given-names>G</given-names>
</name>
<name>
<surname>Aversa</surname> <given-names>T</given-names>
</name>
<name>
<surname>Curr&#xf2;</surname> <given-names>M</given-names>
</name>
<name>
<surname>Curatola</surname> <given-names>S</given-names>
</name>
<name>
<surname>Li Pomi</surname> <given-names>A</given-names>
</name>
<etal/>
</person-group>. <article-title>Meal-related asprosin serum levels are affected by insulin resistance and impaired fasting glucose in children with obesity</article-title>. <source>Front Endocrinol (Lausanne)</source>. (<year>2021</year>) <volume>12</volume>:<elocation-id>805700</elocation-id>. doi:&#xa0;<pub-id pub-id-type="doi">10.3389/fendo.2021.805700</pub-id>
</citation>
</ref>
<ref id="B83">
<label>83</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Harnois-Leblanc</surname> <given-names>S</given-names>
</name>
<name>
<surname>Sylvestre</surname> <given-names>MP</given-names>
</name>
<name>
<surname>Van Hulst</surname> <given-names>A</given-names>
</name>
<name>
<surname>Barnett</surname> <given-names>TA</given-names>
</name>
<name>
<surname>Mathieu</surname> <given-names>M</given-names>
</name>
<name>
<surname>Mesidor</surname> <given-names>M</given-names>
</name>
<etal/>
</person-group>. <article-title>Estimating causal effects of physical activity and sedentary behaviours on the development of type 2 diabetes in at-risk children from childhood to late adolescence: an analysis of the QUALITY cohort</article-title>. <source>Lancet Child Adolesc Health</source>. (<year>2023</year>) <volume>7</volume>:<fpage>37</fpage>&#x2013;<lpage>46</lpage>. doi:&#xa0;<pub-id pub-id-type="doi">10.1016/S2352-4642(22)00278-4</pub-id>
</citation>
</ref>
<ref id="B84">
<label>84</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ying</surname> <given-names>W</given-names>
</name>
<name>
<surname>Fu</surname> <given-names>W</given-names>
</name>
<name>
<surname>Lee</surname> <given-names>YS</given-names>
</name>
<name>
<surname>Olefsky</surname> <given-names>JM</given-names>
</name>
</person-group>. <article-title>The role of macrophages in obesity-associated islet inflammation and &#x3b2;-cell abnormalities</article-title>. <source>Nat Rev Endocrinol</source>. (<year>2020</year>) <volume>16</volume>:<fpage>81</fpage>&#x2013;<lpage>90</lpage>. doi:&#xa0;<pub-id pub-id-type="doi">10.1038/s41574-019-0286-3</pub-id>
</citation>
</ref>
<ref id="B85">
<label>85</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Feinstein</surname> <given-names>R</given-names>
</name>
<name>
<surname>Kanety</surname> <given-names>H</given-names>
</name>
<name>
<surname>Papa</surname> <given-names>MZ</given-names>
</name>
<name>
<surname>Lunenfeld</surname> <given-names>B</given-names>
</name>
<name>
<surname>Karasik</surname> <given-names>A</given-names>
</name>
</person-group>. <article-title>Tumor necrosis factor-alpha suppresses insulin-induced tyrosine phosphorylation of insulin receptor and its substrates</article-title>. <source>J Biol Chem</source>. (<year>1993</year>) <volume>268</volume>:<page-range>26055&#x2013;8</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1016/S0021-9258(19)74276-8</pub-id>
</citation>
</ref>
<ref id="B86">
<label>86</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Sunil</surname> <given-names>B</given-names>
</name>
<name>
<surname>Ashraf</surname> <given-names>AP</given-names>
</name>
</person-group>. <article-title>Dyslipidemia in pediatric type 2 diabetes mellitus</article-title>. <source>Curr Diabetes Rep</source>. (<year>2020</year>) <volume>20</volume>:<fpage>53</fpage>. doi:&#xa0;<pub-id pub-id-type="doi">10.1007/s11892-020-01336-6</pub-id>
</citation>
</ref>
<ref id="B87">
<label>87</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Wang</surname> <given-names>Y</given-names>
</name>
<name>
<surname>Viscarra</surname> <given-names>J</given-names>
</name>
<name>
<surname>Kim</surname> <given-names>SJ</given-names>
</name>
<name>
<surname>Sul</surname> <given-names>HS</given-names>
</name>
</person-group>. <article-title>Transcriptional regulation of hepatic lipogenesis</article-title>. <source>Nat Rev Mol Cell Biol</source>. (<year>2015</year>) <volume>16</volume>:<page-range>678&#x2013;89</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1038/nrm4074</pub-id>
</citation>
</ref>
<ref id="B88">
<label>88</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Stumvoll</surname> <given-names>M</given-names>
</name>
<name>
<surname>Goldstein</surname> <given-names>BJ</given-names>
</name>
<name>
<surname>van Haeften</surname> <given-names>TW</given-names>
</name>
</person-group>. <article-title>Type 2 diabetes: principles of pathogenesis and therapy</article-title>. <source>Lancet</source>. (<year>2005</year>) <volume>365</volume>:<page-range>1333&#x2013;46</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1016/S0140-6736(05)61032-X</pub-id>
</citation>
</ref>
<ref id="B89">
<label>89</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Boden</surname> <given-names>G</given-names>
</name>
<name>
<surname>Shulman</surname> <given-names>GI</given-names>
</name>
</person-group>. <article-title>Free fatty acids in obesity and type 2 diabetes: defining their role in the development of insulin resistance and beta-cell dysfunction</article-title>. <source>Eur J Clin Invest</source>. (<year>2002</year>) <volume>32 Suppl 3</volume>:<fpage>14</fpage>&#x2013;<lpage>23</lpage>. doi:&#xa0;<pub-id pub-id-type="doi">10.1046/j.1365-2362.32.s3.3.x</pub-id>
</citation>
</ref>
<ref id="B90">
<label>90</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Esmaili</surname> <given-names>S</given-names>
</name>
<name>
<surname>Hemmati</surname> <given-names>M</given-names>
</name>
<name>
<surname>Karamian</surname> <given-names>M</given-names>
</name>
</person-group>. <article-title>Physiological role of adiponectin in different tissues: a review</article-title>. <source>Arch Physiol Biochem</source>. (<year>2020</year>) <volume>126</volume>:<fpage>67</fpage>&#x2013;<lpage>73</lpage>. doi:&#xa0;<pub-id pub-id-type="doi">10.1080/13813455.2018.1493606</pub-id>
</citation>
</ref>
<ref id="B91">
<label>91</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Lean</surname> <given-names>ME</given-names>
</name>
<name>
<surname>Leslie</surname> <given-names>WS</given-names>
</name>
<name>
<surname>Barnes</surname> <given-names>AC</given-names>
</name>
<name>
<surname>Brosnahan</surname> <given-names>N</given-names>
</name>
<name>
<surname>Thom</surname> <given-names>G</given-names>
</name>
<name>
<surname>McCombie</surname> <given-names>L</given-names>
</name>
<etal/>
</person-group>. <article-title>Primary care-led weight management for remission of type 2 diabetes (DiRECT): an open-label, cluster-randomised trial</article-title>. <source>Lancet</source>. (<year>2018</year>) <volume>391</volume>:<page-range>541&#x2013;51</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1016/S0140-6736(17)33102-1</pub-id>
</citation>
</ref>
<ref id="B92">
<label>92</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Wing</surname> <given-names>RR</given-names>
</name>
<name>
<surname>Bolin</surname> <given-names>P</given-names>
</name>
<name>
<surname>Brancati</surname> <given-names>FL</given-names>
</name>
<name>
<surname>Bray</surname> <given-names>GA</given-names>
</name>
<name>
<surname>Clark</surname> <given-names>JM</given-names>
</name>
<name>
<surname>Coday</surname> <given-names>M</given-names>
</name>
<etal/>
</person-group>. <article-title>Cardiovascular effects of intensive lifestyle intervention in type 2 diabetes</article-title>. <source>N Engl J Med</source>. (<year>2013</year>) <volume>369</volume>:<page-range>145&#x2013;54</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1056/NEJMoa1212914</pub-id>
</citation>
</ref>
<ref id="B93">
<label>93</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kramer</surname> <given-names>CK</given-names>
</name>
<name>
<surname>Zinman</surname> <given-names>B</given-names>
</name>
<name>
<surname>Choi</surname> <given-names>H</given-names>
</name>
<name>
<surname>Retnakaran</surname> <given-names>R</given-names>
</name>
</person-group>. <article-title>Predictors of sustained drug-free diabetes remission over 48 weeks following short-term intensive insulin therapy in early type 2 diabetes</article-title>. <source>BMJ Open Diabetes Res Care</source>. (<year>2016</year>) <volume>4</volume>:<elocation-id>e000270</elocation-id>. doi:&#xa0;<pub-id pub-id-type="doi">10.1136/bmjdrc-2016-000270</pub-id>
</citation>
</ref>
<ref id="B94">
<label>94</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Pyle</surname> <given-names>L</given-names>
</name>
<name>
<surname>Kelsey</surname> <given-names>MM</given-names>
</name>
</person-group>. <article-title>Youth-onset type 2 diabetes: translating epidemiology into clinical trials</article-title>. <source>Diabetologia</source>. (<year>2021</year>) <volume>64</volume>:<page-range>1709&#x2013;16</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1007/s00125-021-05480-w</pub-id>
</citation>
</ref>
<ref id="B95">
<label>95</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Wang</surname> <given-names>J</given-names>
</name>
<name>
<surname>Lin</surname> <given-names>H</given-names>
</name>
<name>
<surname>Chiavaroli</surname> <given-names>V</given-names>
</name>
<name>
<surname>Jin</surname> <given-names>B</given-names>
</name>
<name>
<surname>Yuan</surname> <given-names>J</given-names>
</name>
<name>
<surname>Huang</surname> <given-names>K</given-names>
</name>
<etal/>
</person-group>. <article-title>High prevalence of cardiometabolic comorbidities among children and adolescents with severe obesity from a large metropolitan centre (Hangzhou, China)</article-title>. <source>Front Endocrinol (Lausanne)</source>. (<year>2022</year>) <volume>13</volume>:<elocation-id>807380</elocation-id>. doi:&#xa0;<pub-id pub-id-type="doi">10.3389/fendo.2022.807380</pub-id>
</citation>
</ref>
<ref id="B96">
<label>96</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Zheng</surname> <given-names>Y</given-names>
</name>
<name>
<surname>Ley</surname> <given-names>SH</given-names>
</name>
<name>
<surname>Hu</surname> <given-names>FB</given-names>
</name>
</person-group>. <article-title>Global aetiology and epidemiology of type 2 diabetes mellitus and its complications</article-title>. <source>Nat Rev Endocrinol</source>. (<year>2018</year>) <volume>14</volume>:<fpage>88</fpage>&#x2013;<lpage>98</lpage>. doi:&#xa0;<pub-id pub-id-type="doi">10.1038/nrendo.2017.151</pub-id>
</citation>
</ref>
<ref id="B97">
<label>97</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Morrish</surname> <given-names>NJ</given-names>
</name>
<name>
<surname>Wang</surname> <given-names>SL</given-names>
</name>
<name>
<surname>Stevens</surname> <given-names>LK</given-names>
</name>
<name>
<surname>Fuller</surname> <given-names>JH</given-names>
</name>
<name>
<surname>Keen</surname> <given-names>H</given-names>
</name>
</person-group>. <article-title>Mortality and causes of death in the WHO Multinational Study of Vascular Disease in Diabetes</article-title>. <source>Diabetologia</source>. (<year>2001</year>) <volume>44 Suppl 2</volume>:<page-range>S14&#x2013;21</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1007/PL00002934</pub-id>
</citation>
</ref>
<ref id="B98">
<label>98</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Hounkpatin</surname> <given-names>H</given-names>
</name>
<name>
<surname>Stuart</surname> <given-names>B</given-names>
</name>
<name>
<surname>Farmer</surname> <given-names>A</given-names>
</name>
<name>
<surname>Dambha-Miller</surname> <given-names>H</given-names>
</name>
</person-group>. <article-title>Association of type 2 diabetes remission and risk of cardiovascular disease in pre-defined subgroups</article-title>. <source>Endocrinol Diabetes Metab</source>. (<year>2021</year>) <volume>4</volume>:<elocation-id>e00280</elocation-id>. doi:&#xa0;<pub-id pub-id-type="doi">10.1002/edm2.280</pub-id>
</citation>
</ref>
<ref id="B99">
<label>99</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Jefferies</surname> <given-names>C</given-names>
</name>
<name>
<surname>Carter</surname> <given-names>P</given-names>
</name>
<name>
<surname>Reed</surname> <given-names>PW</given-names>
</name>
<name>
<surname>Cutfield</surname> <given-names>W</given-names>
</name>
<name>
<surname>Mouat</surname> <given-names>F</given-names>
</name>
<name>
<surname>Hofman</surname> <given-names>PL</given-names>
</name>
<etal/>
</person-group>. <article-title>The incidence, clinical features, and treatment of type 2 diabetes in children &lt;15 yr in a population-based cohort from Auckland, New Zealand, 1995&#x2013;2007</article-title>. <source>Pediatr Diabetes</source>. (<year>2012</year>) <volume>13</volume>:<fpage>294</fpage>&#x2013;<lpage>300</lpage>. doi:&#xa0;<pub-id pub-id-type="doi">10.1111/j.1399-5448.2012.00851.x</pub-id>
</citation>
</ref>
<ref id="B100">
<label>100</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Deusdar&#xe1;</surname> <given-names>R</given-names>
</name>
<name>
<surname>de Moura Souza</surname> <given-names>A</given-names>
</name>
<name>
<surname>Szklo</surname> <given-names>M</given-names>
</name>
</person-group>. <article-title>Association between obesity, overweight, elevated waist circumference, and insulin resistance markers among Brazilian adolescent students</article-title>. <source>Nutrients</source>. (<year>2022</year>) <volume>14</volume>:<page-range>3487</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.3390/nu14173487</pub-id>
</citation>
</ref>
<ref id="B101">
<label>101</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Xu</surname> <given-names>ZR</given-names>
</name>
<name>
<surname>Du</surname> <given-names>HW</given-names>
</name>
<name>
<surname>Cui</surname> <given-names>LW</given-names>
</name>
<name>
<surname>Zheng</surname> <given-names>RX</given-names>
</name>
<name>
<surname>Li</surname> <given-names>GM</given-names>
</name>
<name>
<surname>Wei</surname> <given-names>HY</given-names>
</name>
<etal/>
</person-group>. <article-title>Association of &#x3b2;-cell function and insulin resistance with pediatric type 2 diabetes among Chinese children</article-title>. <source>World J Diabetes</source>. (<year>2021</year>) <volume>12</volume>:<page-range>1292&#x2013;303</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.4239/wjd.v12.i8.1292</pub-id>
</citation>
</ref>
<ref id="B102">
<label>102</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Yoon</surname> <given-names>JS</given-names>
</name>
<name>
<surname>Lee</surname> <given-names>HJ</given-names>
</name>
<name>
<surname>Jeong</surname> <given-names>HR</given-names>
</name>
<name>
<surname>Shim</surname> <given-names>YS</given-names>
</name>
<name>
<surname>Kang</surname> <given-names>MJ</given-names>
</name>
<name>
<surname>Hwang</surname> <given-names>IT</given-names>
</name>
</person-group>. <article-title>Triglyceride glucose index is superior biomarker for predicting type 2 diabetes mellitus in children and adolescents</article-title>. <source>Endocr J</source>. (<year>2022</year>) <volume>69</volume>:<page-range>559&#x2013;65</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1507/endocrj.EJ21-0560</pub-id>
</citation>
</ref>
<ref id="B103">
<label>103</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Khan</surname> <given-names>MS</given-names>
</name>
<name>
<surname>Cuda</surname> <given-names>S</given-names>
</name>
<name>
<surname>Karere</surname> <given-names>GM</given-names>
</name>
<name>
<surname>Cox</surname> <given-names>LA</given-names>
</name>
<name>
<surname>Bishop</surname> <given-names>AC</given-names>
</name>
</person-group>. <article-title>Breath biomarkers of insulin resistance in pre-diabetic Hispanic adolescents with obesity</article-title>. <source>Sci Rep</source>. (<year>2022</year>) <volume>12</volume>:<fpage>339</fpage>. doi:&#xa0;<pub-id pub-id-type="doi">10.1038/s41598-021-04072-3</pub-id>
</citation>
</ref>
<ref id="B104">
<label>104</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Mora-Ortiz</surname> <given-names>M</given-names>
</name>
<name>
<surname>Alcala-Diaz</surname> <given-names>JF</given-names>
</name>
<name>
<surname>Rangel-Zu&#xf1;iga</surname> <given-names>OA</given-names>
</name>
<name>
<surname>Arenas-de Larriva</surname> <given-names>AP</given-names>
</name>
<name>
<surname>Abollo-Jimenez</surname> <given-names>F</given-names>
</name>
<name>
<surname>Luque-Cordoba</surname> <given-names>D</given-names>
</name>
<etal/>
</person-group>. <article-title>Metabolomics analysis of type 2 diabetes remission identifies 12 metabolites with predictive capacity: a CORDIOPREV clinical trial study</article-title>. <source>BMC Med</source>. (<year>2022</year>) <volume>20</volume>:<fpage>373</fpage>. doi:&#xa0;<pub-id pub-id-type="doi">10.1186/s12916-022-02566-z</pub-id>
</citation>
</ref>
<ref id="B105">
<label>105</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Steven</surname> <given-names>S</given-names>
</name>
<name>
<surname>Hollingsworth</surname> <given-names>KG</given-names>
</name>
<name>
<surname>Al-Mrabeh</surname> <given-names>A</given-names>
</name>
<name>
<surname>Avery</surname> <given-names>L</given-names>
</name>
<name>
<surname>Aribisala</surname> <given-names>B</given-names>
</name>
<name>
<surname>Caslake</surname> <given-names>M</given-names>
</name>
<etal/>
</person-group>. <article-title>Very low-calorie diet and 6 months of weight stability in type 2 diabetes: pathophysiological changes in responders and nonresponders</article-title>. <source>Diabetes Care</source>. (<year>2016</year>) <volume>39</volume>:<page-range>808&#x2013;15</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.2337/dc15-1942</pub-id>
</citation>
</ref>
<ref id="B106">
<label>106</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Steven</surname> <given-names>S</given-names>
</name>
<name>
<surname>Taylor</surname> <given-names>R</given-names>
</name>
</person-group>. <article-title>Restoring normoglycaemia by use of a very low calorie diet in long- and short-duration Type 2 diabetes</article-title>. <source>Diabetes Med</source>. (<year>2015</year>) <volume>32</volume>:<page-range>1149&#x2013;55</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1111/dme.12722</pub-id>
</citation>
</ref>
<ref id="B107">
<label>107</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Zou</surname> <given-names>D</given-names>
</name>
<name>
<surname>Zhang</surname> <given-names>Z</given-names>
</name>
<name>
<surname>Ji</surname> <given-names>L</given-names>
</name>
</person-group>. <article-title>Consensus of chinese experts on the management of type 2 diabetes</article-title>. <source>Chin J Diabetes</source>. (<year>2021</year>) <volume>29</volume>:<page-range>641&#x2013;52</page-range>.</citation>
</ref>
<ref id="B108">
<label>108</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Fujihara</surname> <given-names>K</given-names>
</name>
<name>
<surname>Khin</surname> <given-names>L</given-names>
</name>
<name>
<surname>Murai</surname> <given-names>K</given-names>
</name>
<name>
<surname>Yamazaki</surname> <given-names>Y</given-names>
</name>
<name>
<surname>Tsuruoka</surname> <given-names>K</given-names>
</name>
<name>
<surname>Yagyuda</surname> <given-names>N</given-names>
</name>
<etal/>
</person-group>. <article-title>Relationship between the magnitude of body mass index reductions and remission in patients with type 2 diabetes in real world settings: Analysis of nationwide patient registry in Japan (JDDM74)</article-title>. <source>Diabetes Obes Metab</source>. (<year>2023</year>) <volume>25</volume>:<page-range>3125&#x2013;35</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1111/dom.15206</pub-id>
</citation>
</ref>
<ref id="B109">
<label>109</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kahn</surname> <given-names>SE</given-names>
</name>
<name>
<surname>Hull</surname> <given-names>RL</given-names>
</name>
<name>
<surname>Utzschneider</surname> <given-names>KM</given-names>
</name>
</person-group>. <article-title>Mechanisms linking obesity to insulin resistance and type 2 diabetes</article-title>. <source>Nature</source>. (<year>2006</year>) <volume>444</volume>:<page-range>840&#x2013;6</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1038/nature05482</pub-id>
</citation>
</ref>
<ref id="B110">
<label>110</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Urakami</surname> <given-names>T</given-names>
</name>
<name>
<surname>Kuwabara</surname> <given-names>R</given-names>
</name>
<name>
<surname>Habu</surname> <given-names>M</given-names>
</name>
<name>
<surname>Yoshida</surname> <given-names>A</given-names>
</name>
<name>
<surname>Okuno</surname> <given-names>M</given-names>
</name>
<name>
<surname>Suzuki</surname> <given-names>J</given-names>
</name>
<etal/>
</person-group>. <article-title>Pharmacologic treatment strategies in children with type 2 diabetes mellitus</article-title>. <source>Clin Pediatr Endocrinol</source>. (<year>2013</year>) <volume>22</volume>:<fpage>1</fpage>&#x2013;<lpage>8</lpage>. doi:&#xa0;<pub-id pub-id-type="doi">10.1297/cpe.22.1</pub-id>
</citation>
</ref>
<ref id="B111">
<label>111</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Hoffman</surname> <given-names>RP</given-names>
</name>
<name>
<surname>Damilano</surname> <given-names>CP</given-names>
</name>
<name>
<surname>Hong</surname> <given-names>KMC</given-names>
</name>
<name>
<surname>Glick</surname> <given-names>BA</given-names>
</name>
<name>
<surname>Kamboj</surname> <given-names>MK</given-names>
</name>
</person-group>. <article-title>Glycemic control, depression, diabetes distress among adolescents with type 2 diabetes: effects of sex, race, insurance, and obesity</article-title>. <source>Acta Diabetol</source>. (<year>2022</year>) <volume>59</volume>:<page-range>1083&#x2013;9</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1007/s00592-022-01902-2</pub-id>
</citation>
</ref>
<ref id="B112">
<label>112</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Walders-Abramson</surname> <given-names>N</given-names>
</name>
<name>
<surname>Venditti</surname> <given-names>EM</given-names>
</name>
<name>
<surname>Ievers-Landis</surname> <given-names>CE</given-names>
</name>
<name>
<surname>Anderson</surname> <given-names>B</given-names>
</name>
<name>
<surname>El Ghormli</surname> <given-names>L</given-names>
</name>
<name>
<surname>Geffner</surname> <given-names>M</given-names>
</name>
<etal/>
</person-group>. <article-title>Relationships among stressful life events and physiological markers, treatment adherence, and psychosocial functioning among youth with type 2 diabetes</article-title>. <source>J Pediatr</source>. (<year>2014</year>) <volume>165</volume>:<fpage>504</fpage>&#x2013;<lpage>8.e1</lpage>. doi:&#xa0;<pub-id pub-id-type="doi">10.1016/j.jpeds.2014.05.020</pub-id>
</citation>
</ref>
<ref id="B113">
<label>113</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Silverstein</surname> <given-names>J</given-names>
</name>
<name>
<surname>Cheng</surname> <given-names>P</given-names>
</name>
<name>
<surname>Ruedy</surname> <given-names>KJ</given-names>
</name>
<name>
<surname>Kollman</surname> <given-names>C</given-names>
</name>
<name>
<surname>Beck</surname> <given-names>RW</given-names>
</name>
<name>
<surname>Klingensmith</surname> <given-names>GJ</given-names>
</name>
<etal/>
</person-group>. <article-title>Depressive symptoms in youth with type 1 or type 2 diabetes: results of the pediatric diabetes consortium screening assessment of depression in diabetes study</article-title>. <source>Diabetes Care</source>. (<year>2015</year>) <volume>38</volume>:<page-range>2341&#x2013;3</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.2337/dc15-0982</pub-id>
</citation>
</ref>
<ref id="B114">
<label>114</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Sellers</surname> <given-names>EAC</given-names>
</name>
<name>
<surname>McLeod</surname> <given-names>L</given-names>
</name>
<name>
<surname>Prior</surname> <given-names>HJ</given-names>
</name>
<name>
<surname>Dragan</surname> <given-names>R</given-names>
</name>
<name>
<surname>Wicklow</surname> <given-names>BA</given-names>
</name>
<name>
<surname>Ruth</surname> <given-names>C</given-names>
</name>
</person-group>. <article-title>Mental health comorbidity is common in children with type 2 diabetes</article-title>. <source>Pediatr Diabetes</source>. (<year>2022</year>) <volume>23</volume>:<page-range>991&#x2013;8</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1111/pedi.13389</pub-id>
</citation>
</ref>
<ref id="B115">
<label>115</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Taylor</surname> <given-names>R</given-names>
</name>
</person-group>. <article-title>Type 2 diabetes: etiology and reversibility</article-title>. <source>Diabetes Care</source>. (<year>2013</year>) <volume>36</volume>:<page-range>1047&#x2013;55</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.2337/dc12-1805</pub-id>
</citation>
</ref>
<ref id="B116">
<label>116</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Astudillo</surname> <given-names>M</given-names>
</name>
<name>
<surname>Tosur</surname> <given-names>M</given-names>
</name>
<name>
<surname>Castillo</surname> <given-names>B</given-names>
</name>
<name>
<surname>Rafaey</surname> <given-names>A</given-names>
</name>
<name>
<surname>Siller</surname> <given-names>AF</given-names>
</name>
<name>
<surname>Nieto</surname> <given-names>J</given-names>
</name>
<etal/>
</person-group>. <article-title>Type 2 diabetes in prepubertal children</article-title>. <source>Pediatr Diabetes</source>. (<year>2021</year>) <volume>22</volume>:<page-range>946&#x2013;50</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1111/pedi.13254</pub-id>
</citation>
</ref>
<ref id="B117">
<label>117</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Matsui</surname> <given-names>T</given-names>
</name>
<name>
<surname>Okada</surname> <given-names>H</given-names>
</name>
<name>
<surname>Hamaguchi</surname> <given-names>M</given-names>
</name>
<name>
<surname>Kurogi</surname> <given-names>K</given-names>
</name>
<name>
<surname>Murata</surname> <given-names>H</given-names>
</name>
<name>
<surname>Ito</surname> <given-names>M</given-names>
</name>
<etal/>
</person-group>. <article-title>The association between the reduction of body weight and new-onset type 2 diabetes remission in middle-aged Japanese men: Population-based Panasonic cohort study 8</article-title>. <source>Front Endocrinol (Lausanne)</source>. (<year>2022</year>) <volume>13</volume>:<elocation-id>1019390</elocation-id>. doi:&#xa0;<pub-id pub-id-type="doi">10.3389/fendo.2022.1019390</pub-id>
</citation>
</ref>
<ref id="B118">
<label>118</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Arslanian</surname> <given-names>S</given-names>
</name>
<name>
<surname>Bacha</surname> <given-names>F</given-names>
</name>
<name>
<surname>Grey</surname> <given-names>M</given-names>
</name>
<name>
<surname>Marcus</surname> <given-names>MD</given-names>
</name>
<name>
<surname>White</surname> <given-names>NH</given-names>
</name>
<name>
<surname>Zeitler</surname> <given-names>P</given-names>
</name>
</person-group>. <article-title>Evaluation and management of youth-onset type 2 diabetes: A position statement by the american diabetes association</article-title>. <source>Diabetes Care</source>. (<year>2018</year>) <volume>41</volume>:<page-range>2648&#x2013;68</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.2337/dci18-0052</pub-id>
</citation>
</ref>
<ref id="B119">
<label>119</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Misra</surname> <given-names>S</given-names>
</name>
<name>
<surname>Ke</surname> <given-names>C</given-names>
</name>
<name>
<surname>Srinivasan</surname> <given-names>S</given-names>
</name>
<name>
<surname>Goyal</surname> <given-names>A</given-names>
</name>
<name>
<surname>Nyriyenda</surname> <given-names>MJ</given-names>
</name>
<name>
<surname>Florez</surname> <given-names>JC</given-names>
</name>
<etal/>
</person-group>. <article-title>Current insights and emerging trends in early-onset type 2 diabetes</article-title>. <source>Lancet Diabetes Endocrinol</source>. (<year>2023</year>) <volume>11</volume>:<page-range>768&#x2013;82</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1016/S2213-8587(23)00225-5</pub-id>
</citation>
</ref>
<ref id="B120">
<label>120</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Inge</surname> <given-names>TH</given-names>
</name>
<name>
<surname>Courcoulas</surname> <given-names>AP</given-names>
</name>
<name>
<surname>Jenkins</surname> <given-names>TM</given-names>
</name>
<name>
<surname>Michalsky</surname> <given-names>MP</given-names>
</name>
<name>
<surname>Helmrath</surname> <given-names>MA</given-names>
</name>
<name>
<surname>Brandt</surname> <given-names>ML</given-names>
</name>
<etal/>
</person-group>. <article-title>Weight loss and health status 3 years after bariatric surgery in adolescents</article-title>. <source>N Engl J Med</source>. (<year>2016</year>) <volume>374</volume>:<page-range>113&#x2013;23</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1056/NEJMoa1506699</pub-id>
</citation>
</ref>
<ref id="B121">
<label>121</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Rosenstock</surname> <given-names>J</given-names>
</name>
<name>
<surname>Kahn</surname> <given-names>SE</given-names>
</name>
<name>
<surname>Johansen</surname> <given-names>OE</given-names>
</name>
<name>
<surname>Zinman</surname> <given-names>B</given-names>
</name>
<name>
<surname>Espeland</surname> <given-names>MA</given-names>
</name>
<name>
<surname>Woerle</surname> <given-names>HJ</given-names>
</name>
<etal/>
</person-group>. <article-title>Effect of linagliptin vs glimepiride on major adverse cardiovascular outcomes in patients with type 2 diabetes: the CAROLINA randomized clinical trial</article-title>. <source>Jama</source>. (<year>2019</year>) <volume>322</volume>:<page-range>1155&#x2013;66</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1001/jama.2019.13772</pub-id>
</citation>
</ref>
<ref id="B122">
<label>122</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Springer</surname> <given-names>SC</given-names>
</name>
<name>
<surname>Silverstein</surname> <given-names>J</given-names>
</name>
<name>
<surname>Copeland</surname> <given-names>K</given-names>
</name>
<name>
<surname>Moore</surname> <given-names>KR</given-names>
</name>
<name>
<surname>Prazar</surname> <given-names>GE</given-names>
</name>
<name>
<surname>Raymer</surname> <given-names>T</given-names>
</name>
<etal/>
</person-group>. <article-title>Management of type 2 diabetes mellitus in children and adolescents</article-title>. <source>Pediatrics</source>. (<year>2013</year>) <volume>131</volume>:<page-range>e648&#x2013;64</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1542/peds.2012-3496</pub-id>
</citation>
</ref>
<ref id="B123">
<label>123</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Gidding</surname> <given-names>SS</given-names>
</name>
<name>
<surname>Dennison</surname> <given-names>BA</given-names>
</name>
<name>
<surname>Birch</surname> <given-names>LL</given-names>
</name>
<name>
<surname>Daniels</surname> <given-names>SR</given-names>
</name>
<name>
<surname>Gillman</surname> <given-names>MW</given-names>
</name>
<name>
<surname>Lichtenstein</surname> <given-names>AH</given-names>
</name>
<etal/>
</person-group>. <article-title>Dietary recommendations for children and adolescents: a guide for practitioners</article-title>. <source>Pediatrics</source>. (<year>2006</year>) <volume>117</volume>:<page-range>544&#x2013;59</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1542/peds.2005-2374</pub-id>
</citation>
</ref>
<ref id="B124">
<label>124</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Yang</surname> <given-names>X</given-names>
</name>
<name>
<surname>Zhou</surname> <given-names>J</given-names>
</name>
<name>
<surname>Shao</surname> <given-names>H</given-names>
</name>
<name>
<surname>Huang</surname> <given-names>B</given-names>
</name>
<name>
<surname>Kang</surname> <given-names>X</given-names>
</name>
<name>
<surname>Wu</surname> <given-names>R</given-names>
</name>
<etal/>
</person-group>. <article-title>Effect of an intermittent calorie-restricted diet on type 2 diabetes remission: A randomized controlled trial</article-title>. <source>J Clin Endocrinol Metab</source>. (<year>2023</year>) <volume>108</volume>:<page-range>1415&#x2013;24</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1210/clinem/dgac661</pub-id>
</citation>
</ref>
<ref id="B125">
<label>125</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Zhang</surname> <given-names>Y</given-names>
</name>
<name>
<surname>Yang</surname> <given-names>Y</given-names>
</name>
<name>
<surname>Huang</surname> <given-names>Q</given-names>
</name>
<name>
<surname>Zhang</surname> <given-names>Q</given-names>
</name>
<name>
<surname>Li</surname> <given-names>M</given-names>
</name>
<name>
<surname>Wu</surname> <given-names>Y</given-names>
</name>
</person-group>. <article-title>The effectiveness of lifestyle interventions for diabetes remission on patients with type 2 diabetes mellitus: A systematic review and meta-analysis</article-title>. <source>Worldviews Evid Based Nurs</source>. (<year>2023</year>) <volume>20</volume>:<fpage>64</fpage>&#x2013;<lpage>78</lpage>. doi:&#xa0;<pub-id pub-id-type="doi">10.1111/wvn.12608</pub-id>
</citation>
</ref>
<ref id="B126">
<label>126</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kim</surname> <given-names>JY</given-names>
</name>
<name>
<surname>Jeon</surname> <given-names>JY</given-names>
</name>
</person-group>. <article-title>Role of exercise on insulin sensitivity and beta-cell function: is exercise sufficient for the prevention of youth-onset type 2 diabetes</article-title>? <source>Ann Pediatr Endocrinol Metab</source>. (<year>2020</year>) <volume>25</volume>:<page-range>208&#x2013;16</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.6065/apem.2040140.070</pub-id>
</citation>
</ref>
<ref id="B127">
<label>127</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Hay</surname> <given-names>J</given-names>
</name>
<name>
<surname>Maximova</surname> <given-names>K</given-names>
</name>
<name>
<surname>Durksen</surname> <given-names>A</given-names>
</name>
<name>
<surname>Carson</surname> <given-names>V</given-names>
</name>
<name>
<surname>Rinaldi</surname> <given-names>RL</given-names>
</name>
<name>
<surname>Torrance</surname> <given-names>B</given-names>
</name>
<etal/>
</person-group>. <article-title>Physical activity intensity and cardiometabolic risk in youth</article-title>. <source>Arch Pediatr Adolesc Med</source>. (<year>2012</year>) <volume>166</volume>:<page-range>1022&#x2013;9</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1001/archpediatrics.2012.1028</pub-id>
</citation>
</ref>
<ref id="B128">
<label>128</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Shaibi</surname> <given-names>GQ</given-names>
</name>
<name>
<surname>Cruz</surname> <given-names>ML</given-names>
</name>
<name>
<surname>Ball</surname> <given-names>GD</given-names>
</name>
<name>
<surname>Weigensberg</surname> <given-names>MJ</given-names>
</name>
<name>
<surname>Salem</surname> <given-names>GJ</given-names>
</name>
<name>
<surname>Crespo</surname> <given-names>NC</given-names>
</name>
<etal/>
</person-group>. <article-title>Effects of resistance training on insulin sensitivity in overweight Latino adolescent males</article-title>. <source>Med Sci Sports Exerc</source>. (<year>2006</year>) <volume>38</volume>:<page-range>1208&#x2013;15</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1249/01.mss.0000227304.88406.0f</pub-id>
</citation>
</ref>
<ref id="B129">
<label>129</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Shah</surname> <given-names>AS</given-names>
</name>
<name>
<surname>Zeitler</surname> <given-names>PS</given-names>
</name>
<name>
<surname>Wong</surname> <given-names>J</given-names>
</name>
<name>
<surname>Pena</surname> <given-names>AS</given-names>
</name>
<name>
<surname>Wicklow</surname> <given-names>B</given-names>
</name>
<name>
<surname>Arslanian</surname> <given-names>S</given-names>
</name>
<etal/>
</person-group>. <article-title>ISPAD Clinical Practice Consensus Guidelines 2022: Type 2 diabetes in children and adolescents</article-title>. <source>Pediatr Diabetes</source>. (<year>2022</year>) <volume>23</volume>:<fpage>872</fpage>&#x2013;<lpage>902</lpage>. doi:&#xa0;<pub-id pub-id-type="doi">10.1111/pedi.13409</pub-id>
</citation>
</ref>
<ref id="B130">
<label>130</label>
<citation citation-type="journal">
<collab>American Diabetes Association Professional Practice Committee</collab>. <article-title>14. Children and adolescents: standards of medical care in diabetes-2022</article-title>. <source>Diabetes Care</source>. (<year>2022</year>) <volume>45</volume>:<page-range>S208&#x2013;s31</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.2337/dc22-S014</pub-id>
</citation>
</ref>
<ref id="B131">
<label>131</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Borghouts</surname> <given-names>LB</given-names>
</name>
<name>
<surname>Keizer</surname> <given-names>HA</given-names>
</name>
</person-group>. <article-title>Exercise and insulin sensitivity: a review</article-title>. <source>Int J Sports Med</source>. (<year>2000</year>) <volume>21</volume>:<fpage>1</fpage>&#x2013;<lpage>12</lpage>. doi:&#xa0;<pub-id pub-id-type="doi">10.1055/s-2000-8847</pub-id>
</citation>
</ref>
<ref id="B132">
<label>132</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Slaght</surname> <given-names>JL</given-names>
</name>
<name>
<surname>Wicklow</surname> <given-names>BA</given-names>
</name>
<name>
<surname>Dart</surname> <given-names>AB</given-names>
</name>
<name>
<surname>Sellers</surname> <given-names>EAC</given-names>
</name>
<name>
<surname>Gabbs</surname> <given-names>M</given-names>
</name>
<name>
<surname>Carino</surname> <given-names>M</given-names>
</name>
<etal/>
</person-group>. <article-title>Physical activity and cardiometabolic health in adolescents with type 2 diabetes: a cross-sectional study</article-title>. <source>BMJ Open Diabetes Res Care</source>. (<year>2021</year>) <volume>9</volume>:<page-range>e002134</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1136/bmjdrc-2021-002134</pub-id>
</citation>
</ref>
<ref id="B133">
<label>133</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Gaylor</surname> <given-names>AS</given-names>
</name>
<name>
<surname>Condren</surname> <given-names>ME</given-names>
</name> <collab>TODAY Study Group</collab>
</person-group>. <article-title>Type 2 diabetes mellitus in the pediatric population</article-title>. <source>Pharmacotherapy</source>. (<year>2004</year>) <volume>24</volume>:<page-range>871&#x2013;8</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1592/phco.24.9.871.36099</pub-id>
</citation>
</ref>
<ref id="B134">
<label>134</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Alfaraidi</surname> <given-names>H</given-names>
</name>
<name>
<surname>Samaan</surname> <given-names>MC</given-names>
</name>
</person-group>. <article-title>Metformin therapy in pediatric type 2 diabetes mellitus and its comorbidities: A review</article-title>. <source>Front Endocrinol (Lausanne)</source>. (<year>2022</year>) <volume>13</volume>:<elocation-id>1072879</elocation-id>. doi:&#xa0;<pub-id pub-id-type="doi">10.3389/fendo.2022.1072879</pub-id>
</citation>
</ref>
<ref id="B135">
<label>135</label>
<citation citation-type="journal">
<article-title>Effects of metformin, metformin plus rosiglitazone, and metformin plus lifestyle on insulin sensitivity and &#x3b2;-cell function in TODAY</article-title>. <source>Diabetes Care</source>. (<year>2013</year>) <volume>36</volume>:<page-range>1749&#x2013;57</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.2337/dc12-2393</pub-id>
</citation>
</ref>
<ref id="B136">
<label>136</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Badaru</surname> <given-names>A</given-names>
</name>
<name>
<surname>Klingensmith</surname> <given-names>GJ</given-names>
</name>
<name>
<surname>Dabelea</surname> <given-names>D</given-names>
</name>
<name>
<surname>Mayer-Davis</surname> <given-names>EJ</given-names>
</name>
<name>
<surname>Dolan</surname> <given-names>L</given-names>
</name>
<name>
<surname>Lawrence</surname> <given-names>JM</given-names>
</name>
<etal/>
</person-group>. <article-title>Correlates of treatment patterns among youth with type 2 diabetes</article-title>. <source>Diabetes Care</source>. (<year>2014</year>) <volume>37</volume>:<fpage>64</fpage>&#x2013;<lpage>72</lpage>. doi:&#xa0;<pub-id pub-id-type="doi">10.2337/dc13-1124</pub-id>
</citation>
</ref>
<ref id="B137">
<label>137</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Bacha</surname> <given-names>F</given-names>
</name>
<name>
<surname>Cheng</surname> <given-names>P</given-names>
</name>
<name>
<surname>Gal</surname> <given-names>RL</given-names>
</name>
<name>
<surname>Kollman</surname> <given-names>C</given-names>
</name>
<name>
<surname>Tamborlane</surname> <given-names>WV</given-names>
</name>
<name>
<surname>Klingensmith</surname> <given-names>GJ</given-names>
</name>
<etal/>
</person-group>. <article-title>Initial presentation of type 2 diabetes in adolescents predicts durability of successful treatment with metformin monotherapy: insights from the pediatric diabetes consortium T2D registry</article-title>. <source>Horm Res Paediatr</source>. (<year>2018</year>) <volume>89</volume>:<fpage>47</fpage>&#x2013;<lpage>55</lpage>. doi:&#xa0;<pub-id pub-id-type="doi">10.1159/000481687</pub-id>
</citation>
</ref>
<ref id="B138">
<label>138</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ard</surname> <given-names>J</given-names>
</name>
<name>
<surname>Fitch</surname> <given-names>A</given-names>
</name>
<name>
<surname>Fruh</surname> <given-names>S</given-names>
</name>
<name>
<surname>Herman</surname> <given-names>L</given-names>
</name>
</person-group>. <article-title>Weight loss and maintenance related to the mechanism of action of glucagon-like peptide 1 receptor agonists</article-title>. <source>Adv Ther</source>. (<year>2021</year>) <volume>38</volume>:<page-range>2821&#x2013;39</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1007/s12325-021-01710-0</pub-id>
</citation>
</ref>
<ref id="B139">
<label>139</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Tamborlane</surname> <given-names>WV</given-names>
</name>
<name>
<surname>Bishai</surname> <given-names>R</given-names>
</name>
<name>
<surname>Geller</surname> <given-names>D</given-names>
</name>
<name>
<surname>Shehadeh</surname> <given-names>N</given-names>
</name>
<name>
<surname>Al-Abdulrazzaq</surname> <given-names>D</given-names>
</name>
<name>
<surname>Vazquez</surname> <given-names>EM</given-names>
</name>
<etal/>
</person-group>. <article-title>Once-weekly exenatide in youth with type 2 diabetes</article-title>. <source>Diabetes Care</source>. (<year>2022</year>) <volume>45</volume>:<page-range>1833&#x2013;40</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.2337/dc21-2275</pub-id>
</citation>
</ref>
<ref id="B140">
<label>140</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Iqbal</surname> <given-names>J</given-names>
</name>
<name>
<surname>Wu</surname> <given-names>HX</given-names>
</name>
<name>
<surname>Hu</surname> <given-names>N</given-names>
</name>
<name>
<surname>Zhou</surname> <given-names>YH</given-names>
</name>
<name>
<surname>Li</surname> <given-names>L</given-names>
</name>
<name>
<surname>Xiao</surname> <given-names>F</given-names>
</name>
<etal/>
</person-group>. <article-title>Effect of glucagon-like peptide-1 receptor agonists on body weight in adults with obesity without diabetes mellitus-a systematic review and meta-analysis of randomized control trials</article-title>. <source>Obes Rev</source>. (<year>2022</year>) <volume>23</volume>:<elocation-id>e13435</elocation-id>. doi:&#xa0;<pub-id pub-id-type="doi">10.1111/obr.13435</pub-id>
</citation>
</ref>
<ref id="B141">
<label>141</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Weghuber</surname> <given-names>D</given-names>
</name>
<name>
<surname>Barrett</surname> <given-names>T</given-names>
</name>
<name>
<surname>Barrientos-P&#xe9;rez</surname> <given-names>M</given-names>
</name>
<name>
<surname>Gies</surname> <given-names>I</given-names>
</name>
<name>
<surname>Hesse</surname> <given-names>D</given-names>
</name>
<name>
<surname>Jeppesen</surname> <given-names>OK</given-names>
</name>
<etal/>
</person-group>. <article-title>Once-weekly semaglutide in adolescents with obesity</article-title>. <source>N Engl J Med</source>. (<year>2022</year>) <volume>387</volume>:<page-range>2245&#x2013;57</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1056/NEJMoa2208601</pub-id>
</citation>
</ref>
<ref id="B142">
<label>142</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>McDonagh</surname> <given-names>MS</given-names>
</name>
<name>
<surname>Selph</surname> <given-names>S</given-names>
</name>
<name>
<surname>Ozpinar</surname> <given-names>A</given-names>
</name>
<name>
<surname>Foley</surname> <given-names>C</given-names>
</name>
</person-group>. <article-title>Systematic review of the benefits and risks of metformin in treating obesity in children aged 18 years and younger</article-title>. <source>JAMA Pediatr</source>. (<year>2014</year>) <volume>168</volume>:<page-range>178&#x2013;84</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1001/jamapediatrics.2013.4200</pub-id>
</citation>
</ref>
<ref id="B143">
<label>143</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kelly</surname> <given-names>AS</given-names>
</name>
<name>
<surname>Auerbach</surname> <given-names>P</given-names>
</name>
<name>
<surname>Barrientos-Perez</surname> <given-names>M</given-names>
</name>
<name>
<surname>Gies</surname> <given-names>I</given-names>
</name>
<name>
<surname>Hale</surname> <given-names>PM</given-names>
</name>
<name>
<surname>Marcus</surname> <given-names>C</given-names>
</name>
<etal/>
</person-group>. <article-title>A randomized, controlled trial of liraglutide for adolescents with obesity</article-title>. <source>N Engl J Med</source>. (<year>2020</year>) <volume>382</volume>:<page-range>2117&#x2013;28</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1056/NEJMoa1916038</pub-id>
</citation>
</ref>
<ref id="B144">
<label>144</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Chadda</surname> <given-names>KR</given-names>
</name>
<name>
<surname>Cheng</surname> <given-names>TS</given-names>
</name>
<name>
<surname>Ong</surname> <given-names>KK</given-names>
</name>
</person-group>. <article-title>GLP-1 agonists for obesity and type 2 diabetes in children: Systematic review and meta-analysis</article-title>. <source>Obes Rev</source>. (<year>2021</year>) <volume>22</volume>:<elocation-id>e13177</elocation-id>. doi:&#xa0;<pub-id pub-id-type="doi">10.1111/obr.13177</pub-id>
</citation>
</ref>
<ref id="B145">
<label>145</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Tamborlane</surname> <given-names>WV</given-names>
</name>
<name>
<surname>Barrientos-P&#xe9;rez</surname> <given-names>M</given-names>
</name>
<name>
<surname>Fainberg</surname> <given-names>U</given-names>
</name>
<name>
<surname>Frimer-Larsen</surname> <given-names>H</given-names>
</name>
<name>
<surname>Hafez</surname> <given-names>M</given-names>
</name>
<name>
<surname>Hale</surname> <given-names>PM</given-names>
</name>
<etal/>
</person-group>. <article-title>Liraglutide in children and adolescents with type 2 diabetes</article-title>. <source>N Engl J Med</source>. (<year>2019</year>) <volume>381</volume>:<page-range>637&#x2013;46</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1056/NEJMoa1903822</pub-id>
</citation>
</ref>
<ref id="B146">
<label>146</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Seo</surname> <given-names>JY</given-names>
</name>
<name>
<surname>Lee</surname> <given-names>CG</given-names>
</name>
<name>
<surname>Choi</surname> <given-names>H</given-names>
</name>
<name>
<surname>Lee</surname> <given-names>HK</given-names>
</name>
<name>
<surname>Lee</surname> <given-names>SY</given-names>
</name>
<name>
<surname>Kim</surname> <given-names>HJ</given-names>
</name>
<etal/>
</person-group>. <article-title>Effect of once weekly dulaglutide for juvenile type 2 Diabetes mellitus and obesity in Korea: a Pilot Study</article-title>. <source>Ann Pediatr Endocrinol Metab</source>. (<year>2023</year>) <volume>28</volume>:<page-range>296-301</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.6065/apem.2244196.098</pub-id>
</citation>
</ref>
<ref id="B147">
<label>147</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ryan</surname> <given-names>PM</given-names>
</name>
<name>
<surname>Seltzer</surname> <given-names>S</given-names>
</name>
<name>
<surname>Hayward</surname> <given-names>NE</given-names>
</name>
<name>
<surname>Rodriguez</surname> <given-names>DA</given-names>
</name>
<name>
<surname>Sless</surname> <given-names>RT</given-names>
</name>
<name>
<surname>Hawkes</surname> <given-names>CP</given-names>
</name>
</person-group>. <article-title>Safety and efficacy of glucagon-like peptide-1 receptor agonists in children and adolescents with obesity: A meta-analysis</article-title>. <source>J Pediatr</source>. (<year>2021</year>) <volume>236</volume>:<fpage>137</fpage>&#x2013;<lpage>47.e13</lpage>. doi:&#xa0;<pub-id pub-id-type="doi">10.1016/j.jpeds.2021.05.009</pub-id>
</citation>
</ref>
<ref id="B148">
<label>148</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Zeitler</surname> <given-names>P</given-names>
</name>
<name>
<surname>Arslanian</surname> <given-names>S</given-names>
</name>
<name>
<surname>Fu</surname> <given-names>J</given-names>
</name>
<name>
<surname>Pinhas-Hamiel</surname> <given-names>O</given-names>
</name>
<name>
<surname>Reinehr</surname> <given-names>T</given-names>
</name>
<name>
<surname>Tandon</surname> <given-names>N</given-names>
</name>
<etal/>
</person-group>. <article-title>ISPAD Clinical Practice Consensus Guidelines 2018: Type 2 diabetes mellitus in youth</article-title>. <source>Pediatr Diabetes</source>. (<year>2018</year>) <volume>19 Suppl 27</volume>:<fpage>28</fpage>&#x2013;<lpage>46</lpage>. doi:&#xa0;<pub-id pub-id-type="doi">10.1111/pedi.2018.19.issue-S27</pub-id>
</citation>
</ref>
<ref id="B149">
<label>149</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Wu</surname> <given-names>S</given-names>
</name>
<name>
<surname>He</surname> <given-names>Y</given-names>
</name>
<name>
<surname>Wu</surname> <given-names>Y</given-names>
</name>
<name>
<surname>Ji</surname> <given-names>Y</given-names>
</name>
<name>
<surname>Hou</surname> <given-names>L</given-names>
</name>
<name>
<surname>Liu</surname> <given-names>X</given-names>
</name>
<etal/>
</person-group>. <article-title>Comparative efficacy and safety of glucose-lowering drugs in children and adolescents with type 2 diabetes: A systematic review and network meta-analysis</article-title>. <source>Front Endocrinol (Lausanne)</source>. (<year>2022</year>) <volume>13</volume>:<elocation-id>897776</elocation-id>. doi:&#xa0;<pub-id pub-id-type="doi">10.3389/fendo.2022.897776</pub-id>
</citation>
</ref>
<ref id="B150">
<label>150</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Hu</surname> <given-names>Y</given-names>
</name>
<name>
<surname>Li</surname> <given-names>L</given-names>
</name>
<name>
<surname>Xu</surname> <given-names>Y</given-names>
</name>
<name>
<surname>Yu</surname> <given-names>T</given-names>
</name>
<name>
<surname>Tong</surname> <given-names>G</given-names>
</name>
<name>
<surname>Huang</surname> <given-names>H</given-names>
</name>
<etal/>
</person-group>. <article-title>Short-term intensive therapy in newly diagnosed type 2 diabetes partially restores both insulin sensitivity and &#x3b2;-cell function in subjects with long-term remission</article-title>. <source>Diabetes Care</source>. (<year>2011</year>) <volume>34</volume>:<page-range>1848&#x2013;53</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.2337/dc10-2105</pub-id>
</citation>
</ref>
<ref id="B151">
<label>151</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Harrison</surname> <given-names>LB</given-names>
</name>
<name>
<surname>Adams-Huet</surname> <given-names>B</given-names>
</name>
<name>
<surname>Raskin</surname> <given-names>P</given-names>
</name>
<name>
<surname>Lingvay</surname> <given-names>I</given-names>
</name>
</person-group>. <article-title>&#x3b2;-cell function preservation after 3.5 years of intensive diabetes therapy</article-title>. <source>Diabetes Care</source>. (<year>2012</year>) <volume>35</volume>:<page-range>1406&#x2013;12</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.2337/dc11-2170</pub-id>
</citation>
</ref>
<ref id="B152">
<label>152</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Russell-Jones</surname> <given-names>D</given-names>
</name>
<name>
<surname>Khan</surname> <given-names>R</given-names>
</name>
</person-group>. <article-title>Insulin-associated weight gain in diabetes&#x2013;causes, effects and coping strategies</article-title>. <source>Diabetes Obes Metab</source>. (<year>2007</year>) <volume>9</volume>:<fpage>799</fpage>&#x2013;<lpage>812</lpage>. doi:&#xa0;<pub-id pub-id-type="doi">10.1111/j.1463-1326.2006.00686.x</pub-id>
</citation>
</ref>
<ref id="B153">
<label>153</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Brown</surname> <given-names>A</given-names>
</name>
<name>
<surname>Guess</surname> <given-names>N</given-names>
</name>
<name>
<surname>Dornhorst</surname> <given-names>A</given-names>
</name>
<name>
<surname>Taheri</surname> <given-names>S</given-names>
</name>
<name>
<surname>Frost</surname> <given-names>G</given-names>
</name>
</person-group>. <article-title>Insulin-associated weight gain in obese type 2 diabetes mellitus patients: What can be done</article-title>? <source>Diabetes Obes Metab</source>. (<year>2017</year>) <volume>19</volume>:<page-range>1655&#x2013;68</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1111/dom.13009</pub-id>
</citation>
</ref>
<ref id="B154">
<label>154</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kramer</surname> <given-names>CK</given-names>
</name>
<name>
<surname>Zinman</surname> <given-names>B</given-names>
</name>
<name>
<surname>Retnakaran</surname> <given-names>R</given-names>
</name>
</person-group>. <article-title>Short-term intensive insulin therapy in type 2 diabetes mellitus: a systematic review and meta-analysis</article-title>. <source>Lancet Diabetes Endocrinol</source>. (<year>2013</year>) <volume>1</volume>:<fpage>28</fpage>&#x2013;<lpage>34</lpage>. doi:&#xa0;<pub-id pub-id-type="doi">10.1016/S2213-8587(13)70006-8</pub-id>
</citation>
</ref>
<ref id="B155">
<label>155</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Zhu</surname> <given-names>X</given-names>
</name>
<name>
<surname>Zhou</surname> <given-names>G</given-names>
</name>
<name>
<surname>Gu</surname> <given-names>X</given-names>
</name>
<name>
<surname>Jiang</surname> <given-names>X</given-names>
</name>
<name>
<surname>Huang</surname> <given-names>H</given-names>
</name>
<name>
<surname>You</surname> <given-names>S</given-names>
</name>
<etal/>
</person-group>. <article-title>Comparison of bariatric surgery and medical therapy for obese adolescents with type 2 diabetes</article-title>. <source>Asian J Surg</source>. (<year>2022</year>) <volume>46</volume>:<page-range>4337-43</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1016/j.asjsur.2022.10.079</pub-id>
</citation>
</ref>
<ref id="B156">
<label>156</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Pratt</surname> <given-names>JSA</given-names>
</name>
<name>
<surname>Browne</surname> <given-names>A</given-names>
</name>
<name>
<surname>Browne</surname> <given-names>NT</given-names>
</name>
<name>
<surname>Bruzoni</surname> <given-names>M</given-names>
</name>
<name>
<surname>Cohen</surname> <given-names>M</given-names>
</name>
<name>
<surname>Desai</surname> <given-names>A</given-names>
</name>
<etal/>
</person-group>. <article-title>ASMBS pediatric metabolic and bariatric surgery guidelines, 2018</article-title>. <source>Surg Obes Relat Dis</source>. (<year>2018</year>) <volume>14</volume>:<fpage>882</fpage>&#x2013;<lpage>901</lpage>. doi:&#xa0;<pub-id pub-id-type="doi">10.1016/j.soard.2018.03.019</pub-id>
</citation>
</ref>
<ref id="B157">
<label>157</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Armstrong</surname> <given-names>SC</given-names>
</name>
<name>
<surname>Bolling</surname> <given-names>CF</given-names>
</name>
<name>
<surname>Michalsky</surname> <given-names>MP</given-names>
</name>
<name>
<surname>Reichard</surname> <given-names>KW</given-names>
</name>
</person-group>. <article-title>Pediatric metabolic and bariatric surgery: evidence, barriers, and best practices</article-title>. <source>Pediatrics</source>. (<year>2019</year>) <volume>144</volume>:<page-range>e20193223</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1542/peds.2019-3223</pub-id>
</citation>
</ref>
<ref id="B158">
<label>158</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Asiri</surname> <given-names>A</given-names>
</name>
<name>
<surname>Alzahrani</surname> <given-names>F</given-names>
</name>
<name>
<surname>Alghamdi</surname> <given-names>H</given-names>
</name>
<name>
<surname>Alamri</surname> <given-names>Z</given-names>
</name>
</person-group>. <article-title>Effect of laparoscopic sleeve gastrectomy on hbA1C level in children with type 2 diabetes mellitus</article-title>. <source>Medicina (Kaunas)</source>. (<year>2022</year>) <volume>58</volume>:<page-range>959</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.3390/medicina58070959</pub-id>
</citation>
</ref>
</ref-list>
</back>
</article>